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INTRODUCTION 
 
 There is an increasing global burden on lower genital tract infections 
among women of reproductive age group (both pregnant and non pregnant) . 
Some of the consequences of these infections are pelvic inflammatory disease, 
abortions, preterm deliveries and also increasing HIV acquisition . Lower genital 
tract infections can also lead to complications in pregnancy as well as infections 
in the new born . These infections are mostly asymptomatic but can lead to 
serious consequences in their reproductive outcome if left untreated. 
 
 Vaginitis refers to a non-specific inflammation of  the vagina characterized 
by watery discharge with burning and itching of the vulva3. The three common 
types of vaginitis includes Bacterial vaginosis (BV), Vulvovaginal candidiasis 
(VVC) and Trichomoniasis. 
 
 BV is a condition characterized by vaginal discharge with raised pH  in 
which normal vaginal flora of Lactobacilli is replaced by a mixed flora of aerobic, 
anaerobic and microaerophilic species18.In the past few decades awareness has 
increased on the importance of bacterial vaginosis in pregnancy, and it has been 
discovered that pregnant women with BV are at risk of adverse pregnancy 
outcomes including spontaneous abortion, premature birth, preterm labour, 
preterm premature rupture of the membranes, amniotic fluid infection, postpartum 
endometritis, and post cesarean wound infections6,7. Therefore BV is an entity 
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receiving extensive attention during  pregnancy and it is found in 15 to 23% of 
pregnant women with up to 50% of patients being asymptomatic21,22,23. 
 
 In normal healthy female mucosal candidiasis, especially vulvovaginal 
candidiasis(VVC), is one of the most common fungal diseases8,9. Approximately  
about 75% of the women suffers at least one episode of VVC during their 
lifetime10,11. The causative agent in most cases is Candida albicans8,10,12. The most 
common predisposing factors are pregnancy, diabetes mellitus, and antibiotic 
treatment8-11. Some studies have shown that in the past few decades vulvovaginitis 
has increased due to the antifungal resistance among the various Candida species 
and change inthe health quality of  women10,13-15. Therefore vulvovaginal 
candidiasis is found to be more common during  pregnancy, and pregnant women 
have higher rates of recurrent infections. 
 
 Trichomoniasis is an infection  caused by a flagellated protozoon, 
Trichomonas vaginalis. The antenatal women infected with this parasite may be at 
risk of unfavourable birth outcomes such as premature rupture of membranes, 
premature labour, and low birth weight 5. Trichomoniasis is associated with a 30% 
increase in low birth weight infants and a 30% increase in risk of preterm births34. 
It is also associated with enhanced predisposition to neoplastic transformation in 
cervical tissues, infertility and a two fold increased risk of transmission of human 
immunodeficiency virus (HIV)34-37 . 
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 Urinary tract infections (UTIs) have a global annual incidence of 
approximately 150 million cases4. It is one of the most common medical 
complications of pregnancy. During pregnancy the increased incidence of UTI is 
due to the physiological and the morphological changes that take place in the 
genitourinary tract24,25. Many hormonal and mechanical changes occur in the body 
during pregnancy26,27.Starting in the 6th week, with peak incidence during 22nd–
24th weeks of gestation, 90% of the pregnant women develop ureteric dilatation 
which  increases  the risk of vesicoureteric reflux and urinary stasis28.Glycosuria 
and aminoaciduria during pregnancy in addition ,provide an excellent culture 
medium for the bacteria in areas of urinarystasis27.These alterations along with 
already short urethra and difficulty with hygiene due to the distended belly in 
pregnancy increase the frequency of UTIs in them. 
 
 UTI in pregnancy may present either as symptomatic infection or as 
asymptomatic bacteriuria. The prevalence of asymptomatic bacteriuria range from 
2% to 10% in the various studies done globally29. The prevalence of UTI 
(including both symptomatic and asymptomatic bacteriuria ) in India in pregnant 
women is reported to range from 3% to 24%25,30-33. UTI in pregnant women can 
increase the chances to develop anaemia, hypertensive diseases of pregnancy, 
chronic renal failure, prematurity, and low birth weight babies39-41. The upper 
UTIs in particular may lead to significant morbidity for both the mother and the 
fetus30,42. 
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 In the association between UTIs and bacterial vaginosis  sexual intercourse 
has an important confounding role16,17.   UTI in females  develop when 
uropathogens almost always from the fecal flora colonize the vagina, ascend into 
the bladder and in some cases into the kidney. Raised vaginal pH because of the 
reduction in number of lactobacilli which produce lactate and hydrogen peroxide 
predispose to genitourinary infections38.UTI and vaginitis during pregnancy have 
risk to both the mother and the fetus. The lives of both can be saved by a single 
step of early diagnosis and treatment . This study is aimed to determine the 
microbiological profile of vaginitis and the association between BV and UTI 
during pregnancy in a tertiary care hospital. 
  
Aims &objectives 
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AIMS & OBJECTIVES 
 
AIM: 
• To identify common causes of infectious vaginitis in pregnancy and to 
determine the risk of urinary tract infections in pregnant women with 
bacterial vaginosis. 
 
Objective: 
 To study type of infectious vaginitis during pregnancy. 
 To isolate UTI pathogens from urine during pregnancy & determine its 
antimicrobial susceptibility pattern. 
 To determine the association between bacterial vaginosis& UTI in 
pregnancy. 
  
Review of Literature 
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REVIEW OF LITERATURE 
 
 Lower genital tract infections comprises of infections in the vulva, vagina 
or cervix.  Infections which affect the vulva and the vagina are called as vulvo-
vaginitis.  Vaginitis is treatable under ordinary conditions but if left untreated can 
spread up to the upper genital organs leading to pelvic inflammatory disease. 
Even gynecological  procedures like menstrual regulation, insertion of IUDs and 
induced abortions can lead to upper genital tract infections43.  These pelvic 
infections can lead to serious consequences like salpingitis and chronic infections 
of the pelvis and may later lead on to ectopic pregnancy or infertility. 
 
 The etiological agents causing vaginitis can be endogenous or exogenous 
in origin. The common ones include bacterial vaginosis, vulvovaginal candidiasis,  
and trichomoniasis. 
 
 Bacterialvaginosis is a conditions where there is replacement of the normal 
indigenous vaginal flora by abnormal bacteria.  It is most often due to overgrowth 
of the commensal organisms.  It is one of the commonest infection among the 
lower genital tract infections in the reproductive age group44.  According to CDC, 
Bacterial vaginosis is not transmitted sexually but conditions like having multiple 
partners predispose to its occurrence46.   The symptoms of bacterial vaginosis are 
homogenous thin vaginal discharge, lower abdominal pain which may be 
associated with foul smell49.  
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 The agents causing bacterial vaginosis are Gardneralla vaginalis, 
Mobiluncus, Prevotella, Peptostreptococci, and Porphyromonas Species44. 
Overgrowth of these agents causes a reduction in the number of normally 
occurring microbial flora in the vaginal tract which is responsible for the 
production of  lactic acid (lacto bacilli).  The agents mentioned above can occur in 
the range of 100-1000 times  than the normal vaginal microbial organisms45.  This 
leads to the development of bacterial vaginosis. 
 
RISK FCTORS OF THE BV46 
CDC has estimated the following risk factor for bacterial vaginosis 
1. Having new sex partner or multiple sex partner 
2. Douching 
 
 Though bacterial vaginosis is not known to be spread by sexual contact but 
still women in the sexually active age-group have more predisposition for the 
occurrence of BV. 
 
 The first diagnosis of BV was made by Amsel et al., who studied  397 
female students and devised criteria to distinguish non-specific vaginitis from the 
bacterial vaginosis21.  He identified that asymptomatic vaginitis was prevalent in  
more than 50 of students with non-specific vaginitis21. 
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AMSEL’S DIAGNOSTIC CRITERIA21 
1. Homogeneous vaginal discharge 
2. Amine odour after the addition of KOH (Whiff test) 
3. Presence of Clue cells in gram strain 
4. Vaginal pH>4.5 
at least 3 out of 4 criteria must be met for the diagnosis of bacterial vaginosis. 
 
 Nugent et al. devised another scoring system comparing the occurrence of 
Lactobacilli, Gardnerella vaginalis or Bacteroides species  and curved gram 
variable bacteria. His scoring system ranged from 0-10 depending upon the 
occurrence of the above organisms22. 
 
NUGENT’S SCORING 
Score 
Lactobacillus 
Morphotype per 
field 
Gardnerella 
Morphotype 
per field 
Curved Bacteria 
(Mobiluncus) 
Per field 
0 >30 0 0 
1 5-30 <1 <1-4 
2 1-4 1-4 >5 
3 <1 5-30 - 
4 0 >30 - 
 
SCORING 
0-3 Normal/No Bacterial vaginosis 
4-6 Intermediate 
7-10 Bacterial vaginosis 
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 Clue cells are vaginal epithelial cells whose cell borders obscured by the 
adherent small cocco bacilli or gram negative rods or gram variable rods.  They 
represent important criteria in Amsel’s criteria for bacterial vaginosis. They can 
be identified on wet mount and Gram stain.  Most often clue cells are obscured by 
mixed flora consisting of Gram-negative bacilli, Gram-variable bacilli and cocco 
bacilli21. 
 
 Bacterial vaginosis is an infection of the vagina caused by mainly  
anaerobic bacteria like Prevotella, Porphyromonas , Peptostreptococci, and 
Gardnerella44. It is a polymicrobial condition caused by mixed organisms. The 
bacterial vaginosisis also called anaerobic vaginosis, haemophilus, and 
gardnerella vaginosis.  Bacterial vaginosis is significantly associated with many 
pathological conditions like chorioamnionitis60.amnionitis49, endometritis51 and 
prematurity.  Anaerobic vaginosis represents a disturbance in the vaginal 
microbial ecosystem. 
 
 Bacterial vaginosis is the leading cause associated with the vaginal 
discharge accounting up to 48% of cases49.  Prevalence of bacterial vaginosis is 
estimated to be about 15 to 23% in pregnant women with up to 50% of patients 
being asymptomatic21,22,23. 
 
 Apart from causing bacterial vaginosis, Gardnerella can also occur as a 
normal vaginal flora.  Studies have shown that there was no difference between 
the occurrence of gardnerella vaginosis or bacterial vaginosis in sexually active 
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and virginal women and therefore bacterial vaginosis is not to be considered as a 
sexually transmitted disease.  Around 17.5-29.3% of women going for induced 
abortion had bacterial vaginosis.  Thus bacterial vaginosis is known to be a 
predisposing factor for miscarriages and pre-term deliveries 22. 
 
 Tsirmpa et al showed an association of 5% between Bacterial vaginosis 
and Trichomoniasis47.  It is plausible that T. vaginalis infection alters the vaginal 
ecology and facilitates the development of BV, or that women with BV have lost 
natural protection against genital tract infections leading to the acquisition of STIs 
like T. vaginalis infection.  Mathivanan et al., showed a significant correlation 
between bacterial vaginosis and other STIs.  Bacterial vaginosis was also found to 
be more prevalent in patients with tubal infertility( 31.5%) than in patients with 
non-tubal infertility44.  Prevalence of bacterial vaginosis in female STD patients 
was 16% more than in the normal population. Similarly, bacterial vaginosis was 
found in 15% of women prisoners.  Higher incidence of bacterial vaginosis was 
seen in rape victims (50%) and sex workers (70%),  the correlation of bacterial 
vaginosis to uro-gential infections was found to be 19.7% in women of 
reproductive age-group49.  The score of greater than 6 by the Nugent’s criteria 
estimates the presence of bacterial vaginosis in infertile women to be around 
19%53. A score of 4-10 is also found in 39% of infertile women53.  Thus infertility 
was found to be correlated with prevalence of bacterial vaginosis.  Tubal 
infertility was found to be significantly associated with women having bacterial 
vaginosis.  Thus bacterial vaginosis is an important cause of tubal infertility.  It is 
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also associated with pre-term deliveries and miscarriages.  Thus women having 
bacterial vaginosis have increased rate of abortions51. 
 
TREATMENT: 
 Bacterial vaginosis treatment in asymptomatic pregnant women at high risk 
(i.e those who have previously delivered a premature infant) for preterm delivery 
with a recommended oral regimen has reduced preterm delivery in three out of 
four randomized control trials. 
 
 Bacterial Vaginosis in pregnant women is treated with metronidazole 
500mg orally twice a day for 7 days or metronidazole 250mg orally three times a 
day for 7 days or clindamycin 300 mg orally twice a day for 7 days. Since 
metronidazole is contraindicated in 1st trimester of pregnancy because of possible 
teratogenic effect , amoxicillin although less effective is suggested as an 
alternative treatment.  
 
TRICHOMONIASIS 
 Trichomonas vaginalis is a sexually transmitted protozoan parasite. Every 
year worldwide around 180 million cases of trichomoniasis occurs49.  It is a 
common sexually transmitted infection and occurs as a mixed infection often with 
other organism like Gonococci. The co-infection rate is around 60%.  The 
spectrum of clinical symptoms can vary from asymptomatic to severe disease.  
This organism is transmitted mainly by sexual intercourse through coitus from the 
male partner.  It comprises of the following symptoms – yellowish green,  
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malodorous, frothy, thin vaginal discharge and comprises of signs like burning 
sensation, itchiness, dysuria and dyspareunia.  The classical sign is erythematous 
vulva and punctuate hemorrhages seen in the vaginal wall.  This is called 
strawberry vagina/cervix54. 
 
MORPHOLOGY 
 Among the Trichomonads, Trichomonas vaginalis is the commonly 
occurring species. The size of the protozoan parasite may range from 7-10 mm55. 
Size and shape may be altered by physio-chemical conditions.  But the parasite is 
mostly seen as pear or oval-shaped in axenic cultures but becomes amoeboid 
when it attaches  to vaginal epithelial cells.  It comprises of five flagella, four 
located on its anterior portion.  The fifth flagellum is incorporated  inside the 
undulating membrane which gives it a quivering motility55.  Nucleus of this 
parasite is located on its anterior portion.  Rod-like structure called axo style 
bisects the parasite longitudinally and terminates  as a sharp point  at its posterior 
end55. This structure is responsible for anchorage of the parasite to the vaginal 
epithelial cells. 
 
CLINICAL MANIFESTATION 
 Clinical patterns of Trichomoniasis may vary from asymptomatic carrier 
state to symptomatic disease comprising of vaginal discharge. This parasite 
infects the squamous epithelium of the vaginal tract. The infection prevails for 
longer period after the first episode55.  Trichomoniasis is the disease of the 
reproductive age-group.  Its incubation period varies from 5-28 days. The clinical 
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picture of the disease can be classified as acute, chronic or asymptomatic56.  Acute 
infection presents as copious leucorrhoea. The disease presents with yellow or 
greenish frothy and mucopurulent  vaginal discharge56.   The disease presents with 
clinical signs and symptoms which are cyclic and can worsen during menstrual 
period.  Important sign in this disease is the fiery red appearing cervix/vagina 
which is called as strawberry appearance57.  This classical description is seen only 
in 2% of patients. Chronic infection presents with symptoms like pruritus, 
dyspareunia and absence of discharge.  Majority of the patients are asymptomatic 
and may have normal vaginal pH and normal vaginal flora.  After infection 
around 50%  of women develop symptoms within 6 months58.  The other organ 
involved in the infection is bartholin’s gland. Complications of this disease may 
include adnexitis, endometritis and pyosalpinx.  These complications may lead to 
cervical erosion and therefore cause infertility and low birth weight.  There are 
many studies showing an increased association between HIV and 
trichomoniasis59,60. 
 
MICROSCOPIC AND CULTURE TECHNIQUES 
 Donne et al., was the first to describe the use of microscope for the 
observation of Trichomonas in vaginal and cervical secretions61.  This technique 
has sensitivity ranging from 38% to as high as 82%62.  Though  this technique is 
cost-effective but has a low sensitivity since this parasite may lose its motility  
within few minutes. Thus it may be the best diagnostic test when done at bed side.  
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The gold standard  for the diagnosis of trichmoniasis is broth culture of the 
organism. This method requires as few as 300-500 parasite per ml of inoculum63. 
 
 Cell culture techniques are also useful for the recovery of Trichomonas 
vaginalis from clinical specimens as demonstrated by Garber  et al., he showed 
that the cell culture was superior to both broth culture and wet mount. 
 
 Stains used are Periodic Acid Schiff (PAS)65,Acridine orange64,Leishman,  
and  Fontana.  Papanicolaou (PAP) stain also shows significant appeal in the 
diagnosis of trichomoniasis. Pap stain is routinely used in gynaecological 
screening of cytological abnormalities. 
 
 All staining techniques have considerable limitations because  the parasite 
appears pear-shaped and may resemble polymorphonuclear leucocytes.  The 
typical morphology of the  parasite are also lost during fixation of the smears66.    
Antigenic markers of Trichomonas can be demonstrated  by immune-blot 
analysis67.  Other techniques used for the diagnosis are complement fixation, 
indirect haemagglutination, gel-diffusion, fluorescent antibody and ELISA.  All 
these techniques detect for the presence of anti-trichomonal antibodies. 
 
TREATMENT 
 Untill 1959, only topical vaginal preparations were available for 
trichomoniasis.  But topical applications were not useful since they did not  
penetrate the vaginal epithelium.  Even after the treatment  the parasite was 
transmitted form the male partner to the females.  Recent available preparations 
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include clotrimazole, providone iodine and nonoxynol-9, which  provide palliative 
cure. Azomycin antibiotic  was found to be highly  effective in the treatment of 
trichomoniasis68.   They produce nitroimidazole which  are cytocidal to the 
parasite  after its diffusion into the organism (Mueller et al.,)69.  These metabolic  
products breakdown the DNA strands of the organisms69.  As a result  cell death 
ensures due to the loss of mitotic activity and  the parasite dies within one hour.  
The cell death is depicted  within 8 hours in cell culture. 
 
 Metronidazole 250mg given orally for 7 day is the standard treatment  for 
trichomoniasis. Both symptomatic and asymptomatic diseases need treatement70.  
Male partner also has to be treated in order to prevent re-infection. Both partner 
treatment has a success rate of almost 95% (Heine et al.,)65.  
 
Trichomonas vaginalis is more common among HIV infected patients. The 
incidence of trichomoniasis  and HIV co-infection ranges between 6-27%. 
Trichomoniasis also predisposes to other STIs.   Its incidence is estimated to be 
around  15% in STI clinics.  In India, prevalence varies between 6 and 10%71. 
 
Trichomonas vaginalis accounts for 20% of infections in women having  
vaginitis.  Prevalence of about 47%  was reported  by Manson et al72,  but this is  
not constant as it may vary from place to place  and study to study72-79. 
Microbiological  diagnosis  is necessary in case of trichomoniasis, a wet mount 
preparation is sufficient for definitive diagnosis of motile Trichomonas.  Thus wet 
mount is useful in diagnosing about 60% infected women who present with 
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clinical symptoms of lower genital  tract infection. Other staining techniques like 
papanicolaou and acridine orange  are often inaccurate  in the diagnosis of the 
trichomoniasis. 
 
Lemos et al., compared  three techniques for the diagnosis of Trichomonas 
vaginalis in HIV positive  and negative women  (wet mount,  microscopy, culture 
and cytology).  The results were 13.9% by culture, 13.5% by cytology and 11.4%  
by wet mount. 
 
 Weise et al.,  stated that wet mount microscopy is a highly  specific 
diagnostic method in case of trichomoniasis79.  It has many advantages  like low-
cost, most  convenient and widely used method for the diagnosis of  
trichomoniasis in a resource constrained laboratory set up.  If examined within ten 
minutes of collection  of sample the results of wet mount are comparable with  
other techniques.  Thus wet mount plays a vital role as a sole screening  test in 
gynecological clinics in the hands of a skilled microscopist.  Culture along with 
wet mount  microscopy significantly yields more information.  This disease  has 
many medical, social and economic implications.  Antenatal complications like 
pre-mature rupture of membranes, pre-mature labor and low birth weight  are 
known to occur  with this infection. Other diseases like cervical cancer, infertility  
and pelvic inflammatory  disease are also associated with this infection.  
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VULVOVAGINAL CANDIDIASIS 
 Candida is a common fungus that affects the mucosa, skin, nails and other 
organs of human body.  Vulvo vaginal candidiasis occurs in around 75% of 
women in reproductive age-group. 40-50%  of them have a second attack. Even 
healthy females grow Candida in SDA cultures.  The vaginal tract is colonized 
with the Candida from the adjacent peri-anal region. By attachment to the vaginal 
epithelial cells it gains access into the vagina. C. albicans adhere more strongly 
than non C. albicans80. 
 
 There are many factors associated  with vulvovaginal candidiasis  like 
uncontrolled Diabetes mellitus ,pregnancy and oral contraceptive pills. Candida 
vaginitis  is more prevalent in the reproductive age group and rare in pre-
menarchial and post-menopausal women.  This shows that the candidiasis is 
highly depended on the influence of hormones. Other factors that predispose to 
candida are anti-microbial therapy, use of corticosteroids, insertion of intra-
uterine devices and increase in the rate of coitus83. Colonization and tissue 
invasion of candiada  is depended upon germination. So the factors which 
enhance the germination (estrogen therapy, pregnancy) increase the chance of 
Candida vaginitis.   
 
 Vulvovaginal candidiasis causes maximum symptoms during the third 
trimester pregnancy  but recurrences can occur throughout pregnancy.  This may 
be due to the high levels of pregnancy hormone that increase the glycogen content 
in the vagina thereby, providing  a rich carbon source for the Candida infection.  It 
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has been found that the adherence of Candida to the vaginal epithelial  cells is 
enhanced by estrogen.  Estrogen87 also enhances  yeast to mycelial 
transformation. Oral contraceptive pills may also cause an increase in Candida 
vaginitis.  Patients with recurrent vulvovaginal candidiasis are to be screened for 
uncontrolled diabetes mellitus.  Thus there is a positive association between 
vulvovaginal candidiasis and diabetes mellitus but most often this may not be 
detected by glucose tolerance test.  Women taking diet with refined sugar may be 
predisposed to candida vaginitis. 
 
Sobel et al., stated that vulvovaginal candidiasis is a common cause of 
morbidity and health related problems in young women80. Recent studies have 
shown that the percentage of non-Candida albicansis on the rise.  Carr P L et al, 
showed that the C. albicansis  found as a normal commensal in around 25% of 
women82 .  More than 75% of women in the reproductive age group will have the 
incidence of vulvovaginal candidiasis and around half of them will have 
recurrence. Recurrent candidal vulvovaginitis is defined  as four or more 
symptomatic infections in one year or three episodes of infection not related  to 
the intake of antibiotics occurring within a year83. Studies  have shown that 10-
30% of recurrence is due to non-Candida albicans species.  Among them common 
ones are Candida glabrata, Candida tropicalis, Candida krusei and Candida 
parapsilosis84. 
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Vulvovaginal candidiasis presents as pruritus (50%), vaginal discharge 
(24%)  and dysuria (33%) other symptoms are burning and stinging sensations but 
these are considered as non-specific symptoms85,86 . 
 
When a woman presents with candida vulvovaginitis, the following points 
must be taken in to account: 
 
1. Presence of uncontrolled diabetes mellitus, diet high in refined sugars, use 
of broad spectrum antibiotics and intake of corticosteriods87. 
2. History of oral and anal sex88. 
3. Factors such a pregnancy, use of oral contraceptives, which indicate state 
of hyper estrogenism89. 
4. Other dermatological diseases also need to be excluded (allergic 
dermatitis). 
5. Presence of immune-suppressive conditions like HIV and immune 
suppressive treatments may reduce the local immunity90. 
6. Presence of other infections (trichomoniasis, bacterial vaginosis). 
7. Trace elements deficiency like magnesium, zinc, calcium91. 
 
LAB DIAGNOSIS 
 A clinical suspicion and proper examination is necessary for the diagnosis.  
Species like C.albicans, C.tropicalis show the presence of pseudohyphae and 
mycelia on direct examination in wet mount92,93.   Culture for Candida is to be 
performed when there is a discrepancy between clinical suspicion and direct 
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examination 90, 93. Now a days culture is mainly performed in commercially 
available  systems. Other methods  like latex agglutination and polymerase chain 
reaction can also be performed.  Culture  is not always  definitive for diagnosis 
since 25% of asymptomatic women can be colonized by Candida and will grow 
Candida in culture94.  So, definitive diagnosis is based on a proper clinical data, 
physical examination, examination of wet mount, Gram stain and  culture. 
Speciation done by sugar fermentation test,sugar assimilation test and by using 
media such as CHROMagar candida medium and cornmeal agar. 
 
Growth on SDA: 
 The colonies appear cream colored ,smooth and pasty. 
 
Gram stain morphology: 
 Gram positive budding yeast cells with or without pseudohyphae. 
 
Sugar fermentation reactions for Candida species130: 
Candida species Glucose Maltose Sucrose Lactose 
C.albicans AG AG - - 
C.troplicalis AG AG AG - 
C.kefyer AG AG AG - 
C.guilliermondii AG - AG - 
C.parapsilosis AG - - - 
C.krusei AG - - - 
C.glabrata AG - - - 
A=Acid production , G=Gas production 
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Sugar assimilation reactions of different Candida species and their growth on 
TRM130: 
Candida spp. Glu Mal Suc Lac Cel Gal Tre Raf Mel Xyl Ino Dul TRM 
C.albicans + + + + + + + - - + - - PP 
C.tropicalis + + + - + + + - - + - - M 
C.kefyer + - + + + + - + - + - - SP 
C.parapsilosis + + + - - + + - - + - - RP 
C.guilliermondii + + + - + + + + + + - + PsP 
C.krusei + - - - - - - - - + - - DP 
C.glabrata + - - - - - + - - + - + PP 
 
Note:Glu=Glucose,Mal=Maltose,Suc=Sucrose,Lac=Lactose,Cel=Cellobiose,Gal=
Galactose,Tre=Trehalose,Raf=Raffinose,Mel=Melibiose,Xyl=Xylose, 
Ino=Inositol ,  Dul=Dulcitol , +=positive reaction,- = negative reaction. 
 
 Tetrazolium Reduction Medium (TRM) :PP=Pale Pink ,OP=Orange Pink, 
M=Maroon, SP=Salmon Pink, RP=Rose Pink, PsP=Pink and pasty, DP=Pink and 
dry. 
 
CHROMagar Candida Medium130: 
 It is selective and differential type of chromogenic medium, which is useful 
for identification of various Candida species . Due to chromogenic substrate in the 
medium, the colony morphology and color have been well defined when it is used 
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to isolate the yeasts. The CHROMagar candida shows following colors of 
colonies after incubation at 30ºc for a period of 48 to 72 hrs:  
 
 C.albicans : Light green , C.dubliniensis :Dark green ,C.glabrata :Pink to 
purple , C.krusei :Pink , C.parapsilosis :Cream to pale pink , C.tropicalis :Blue 
with pink halo. 
 
Cornmeal agar130: 
 Benham in 1931 described use of cornmeal agar (CMA) for stimulation of 
chlamydospore formation. 
 
 C.albicans: Elongated pseudohyphal cells with large clusters of 
blastoconidia in junctures between cells, sessile intercalary and many terminal 
chlamydospores seen. 
 
 C.dubliniensis : Clusters of round blastoconidia at the septa, large thick 
walled terminal chlamydospores. 
 
 C.tropicalis: Blastoconidia single or small groups along pseudohyphae. Fir 
tree appearance. 
 
 C.parapsilosis: Short, thin marked curved pseudohyphal cells develop into 
large giant pseudohyphal cells. 
 
 C.krusei:Presence of pseudohyphae with elongated blastoconidia gives 
match stick appearance. 
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 C.kefyr:Pseudohyphae with elongated blastoconidia which is log in stream 
appearance. 
 
 C.glabrata:Nopseudohyphae,small oval budding yeast cells single 
terminal budding. 
 
 C.lusitaniae: Occasional blastoconidia at septa with short distinctly curved 
pseudohyphae. 
 
 C.guilliermondii: True hyphae absent.Small groups of blastoconidia at 
septa few short pseudohyphae 
 
TREATMENT 
 Today the treatment of choice is a single dose of fluconazole 150 mg/ 
intra-vaginal clotrimazole 100mg daily for 7 days.  The side effects of this therapy 
are gastro-intestinal discomfort, skin rash, headache and tiredness  which are 
tolerated.  Azole groups of drugs are known to cause arrhythmias when given 
along with H1 anti-histamines like astemizole95. 
 
URINARY TRACT INFECTIONS: 
 Urinary tract infections (UTIs) in general can be symptomatic or 
asymptomatic. Symptomatic UTI can be divided into infections restricted to the 
lower urinary tract (bladder and urethra) , to the upper urinary tract (kidney) or 
infections with systemic involvement, which is urosepticemia. 
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DEFINITIONS 50 
Symptomatic Urinary Tract Infection 
 Cystitis is defined as an inflammation of the urinary bladder. Urethritis is 
an inflammation of the urethra. Both are most commonly caused by a bacterial 
infection; in which case, they are also referred to as lower UTIs. Classic 
symptoms of lower UTIs are dysuria, urinary frequency, and suprapubic pain 
sometimes in combination with hematuria, but normally without fever. The extent 
of symptoms varies between different patients and can be very mild to severe. 
Other diseases can mimic lower urinary tract bacterial infections like vaginitis, 
interstitial cystitis, and pelvic inflammatory disease. 
 
Asymptomatic Bacteriuria 
 Asymptomatic bacteriuria refers to bacteriuria inpatients with no clinical 
UTI symptoms. For women ≥10⁵ colony forming units (CFU) per ml in two 
consecutive clean-catch urine samples is required for the diagnosis of 
asymptomatic bacteriuria, whereas for men only one clean catch urine sample 
with ≥10⁵ CFU per mL is required—or a single catheterized urine specimen with 
one single bacterial strain of ≥ 10² CFU per mL in women or men96.  
 
CLASSIFICATION 
 Acute cystitis and urethritis can be classified as uncomplicated versus 
complicated UTI, nosocomial versus community-acquired UTI, and sporadic 
versus recurrent UTI. 
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 Uncomplicated UTI occurs in persons with normal urinary tract, whereas 
complicated UTI occurs in individuals with functional or structural changes, 
implying deteriorated voiding predisposing for bacteriuria. 
 
 Nosocomial UTI are infections that occur 48 hours or more after admission 
to the hospital or as a result of healthcare, whereas community-acquired UTI are 
UTIs not included in the previous group. 
 
 Sporadic UTI include a single UTI treated with antibiotics during 6 months 
or maximum two UTIs needing antibiotics during 1 year, whereas recurrent UTI 
comprise atleast two antibiotic treated UTIs during 6 months or three ormore 
antibiotic treated UTI during 1 year. 
 
 Recurrent UTI can be further divided into relapse or reinfection. Relapse 
infection includes a recurrent infection with the same bacteria as the previous 
UTI, whereas a reinfection is caused by different bacteria than in the previous 
infection. 
 
ETIOLOGY 
 The most common bacterial uropathogen is Escherichia coli , causing more 
than 80% of UTIs among female ambulatory patients. In men and hospitalized 
patients, E. coli is still the most commonly isolated bacteria, but with a lower 
frequency. Other common uropathogenic bacteria include Klebsiella pneumoniae, 
Proteus mirabilis ,Enterococci, Streptococcus agalactiae, and Staphylococcus 
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saprophyticus97,98. S. saprophyticus is the only urinary pathogen with a seasonal 
variation, being most common during the late summer and early autumn months99. 
 
EPIDEMIOLOGY 
 Prevalence of UTI is different depending on the age and gender of the 
patient.  
 
 During the reproductive period, the gender difference becomes even more 
pronounced and UTIs are some 50-fold more common in women as compared to 
men.  
 
 Approximately 20% of women between 24 and 64 years old have at least 
one episode of dysuria each year, most of these being caused by bacterial 
infections100.Almost half of all women will experience at least one episode of UTI 
during their lifetime 101 and about 25% of these have recurrent infections. 
 
PATHOGENESIS48 
Routes of Infection : 
 Bacteria can invade and cause a UTI via three major routes: ascending, 
hematogenous, and lymphatic pathways.  Ascending route is the most common 
course of infection in females, ascent in association with instrumentation (e.g., 
urinary catheterization, cystoscopy) is the most common cause of hospital-
acquired UTIs in both sexes. For UTIs to occur by the ascending pathway, enteric 
gram-negative bacteria and other microorganisms must be able to colonize the 
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vaginal cavity or the periurethral area. Once these organisms gain access to the 
bladder, they multiply and ascend up the ureters to the kidneys. UTIs occur more 
often in women than men, at least partially because of the short female urethra 
and its proximity to the anus.  Sexual activity can increase chances of bacterial 
contamination of the female urethra. 
 
 UTIs that occur by the hematogenous route spread usually occurs as a 
result of bacteremia. Any systemic infection can lead to seeding of the kidney, but 
certain organisms, such as Staphylococcus aureus or Salmonella spp., are 
particularly invasive. Although most infections involving the kidneys are acquired 
through the ascending route, yeast (usually Candida albicans), Mycobacterium 
tuberculosis, Salmonella spp., Leptospira spp., or Staphylococcus aureus in the 
urine often indicates pyelonephritis acquired via hematogenous spread, or the 
descending route.  
 
The Host-Parasite Relationship: 
 Females in particular, are colonized in the vaginal or periurethral area with 
organisms originating from the gastrointestinal tract, yet they do not develop 
urinary infections. Whether an organism is able to colonize and then cause a UTI 
is determined in large part by a complex interplay of host and microbial factors. 
 
 Mostly, the host defense mechanisms are able to eliminate the organisms. 
Urine itself is inhibitory to some of the urethral flora such as anaerobes. In 
addition, if urine has a low pH, high or low osmolality, high urea concentration, or 
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high organic acid content, even organisms capable of growth in the urinary tract 
may be inhibited. 
 
 Any interference with the act of normal voiding, such as mechanical 
obstruction resulting from pregnancy, kidney stones or strictures, will promote the 
development of UTI.  
 
 Valve mechanism at the junction of the ureter and bladder prevents the 
reflux (backward flow) of urine from the bladder to the upper urinary tract. 
Therefore, if the function of these valves is inhibited or compromised in any way, 
such as by obstruction or congenital abnormalities, urine reflux provides a direct 
route for organisms to reach the kidney. 
 
 Hormonal changes associated with pregnancy and their effects on the 
urinary tract increase the chance for urine reflux into the upper urinary tract. 
 
 Activation of the host immune response by uropathogens also plays a key 
role in fending off infection. For example, bacterial contact with urothelial cells 
initiates an immune response via a variety of signaling pathways. Bacterial 
lipopolysaccharide  activates host cells to release cytokines such as tumor necrosis 
factor and interferon-gamma. In addition, bacteria can activate the complement 
cascade, leading to the production of biologically active components such as 
opsonins, as well as augment the host’s adaptive immune response. Host factors 
that lead to host susceptibility or resistance to uropathogens have been identified. 
For example, a glycoprotein synthesized exclusively by epithelial cells in a 
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specific anatomic location in the kidney, referred to as Tamm-Horsfall protein or 
uromodulin, serves as an anti-adherence factor by binding to E. coli–expressing 
type 1 fimbriae .Defensins, a group of small antimicrobial peptides, are produced 
by a variety of host cells such as macrophages, neutrophils, and cells in the 
urinary tract and attach to the bacterial cell, eventually causing its death. 
 
 Although many microorganisms can cause UTIs, most cases are a result of 
infection by a few organisms. To illustrate, only a limited number of serogroups 
of E. coli cause a significant proportion of UTIs. UPEC possesses virulence 
factors that enhance their ability to colonize and invade the urinary tract. Some of 
these virulence factors include increased adherence to vaginal and uroepithelial 
cells by bacterial surface structures (adhesins, in particular, pili), alpha-hemolysin 
production, and resistance to serum killing activity . Also, genome sequences of 
some UPEC strains have been determined, indicating that several potential 
virulence factor genes associated with the acquisition and development of UTIs 
are encoded on pathogenicity islands (e.g., hemolysins and E. coli P. fimbriae). 
Uropathogenic E. coli (UPEC) possess pathogenicity islands containing a variety 
of virulence factors. By definition, pathogenicity islands contain genes that are 
associated with virulence and are absent from a virulent or less virulent strains of 
the same species. 
 
 The importance of adherence in the pathogenesis of UTIs has also been 
demonstrated with other species of bacteria.  Proteus strains appear to be uniquely 
suited to cause significant disease in the urinary tract. Data indicate that these 
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strains are able to facilitate their adherence to the mucosa of kidneys. Also, 
Proteus is able to hydrolyze urea via urease production. This results in an increase 
in urine pH that is directly toxic to kidney cells and also stimulates the formation 
of kidney stones. 
 
 Similar findings have been made with Klebsiellaspp. Staphylococcus 
saprophyticus also adheres better to uroepithelial cells than does S. aureus or S. 
epidermidis. 
 
 Other bacterial characteristics may be important in the pathogenesis of 
UTIs. Motility may be important for organisms to ascend to the upper urinary 
tract against the flow of urine and cause pyelonephritis. Some organisms 
demonstrate greater production of K antigen (capsuleor outer cell wall); this 
antigen protects bacteria from being phagocytosed. 
 
 Finally, despite numerous host defenses and even antibiotic treatments that 
can effectively sterilize the urine, a significant proportion of patients have 
recurrent UTIs. Studies show that uropathogens can invade superficial epithelial 
cells in the bladder and replicate, forming large foci of intracellular E. coli. This 
invasion of bladder epithelial cells triggers the host immune response, which in 
turn causes the superficial cells to exfoliate within hours following infection. 
Although this exfoliation is considered a host defense mechanism by eliminating 
infected cells, intracellular organisms are able to reemerge from the bladder 
epithelial cells and invade the underlying, new superficial layer of epithelial cells, 
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consequently persisting within the urinary tract.  Anderson and colleagues 
reported that intracellular bacteria mature into numerous, large protrusions on the 
bladder surface they referred to as “pods.” This bacterial organization—in which 
the intracellular bacteria are embedded in a fibrous, polysaccharide-rich matrix 
resembling that of a biofilm—may help further explain the persistence of bladder 
infections despite strong host defenses. 
 
SYMPTOMS 
 The symptoms of a UTI substantially differ depending on age and type of 
infection. The adults with urethritis and cystitis typically have frequent and urgent 
voiding of small volumes of urine and dysuria and nocturia is common. Sensation 
of lower abdominal discomfort also is a frequent symptom. The urine may be 
turbid or even bloody in one third of cases102.  Some infections may progress after 
1 or 2 days to develop a clinical picture of upper UTI, including flank or 
abdominal pain, fever, and vomiting, but acute cystitis  seldom progresses to 
cause septicemia.  
 
SAMPLE COLLECTION 
 Urine sample must be collected in universal container. Clean the area 
around urethral opening with soap and clean water then rinse, dry the area with a 
sterile guazepad ; Hold the labia apart and collect midstream voided urine. For 
patients with an indwelling urinary catheter the urine sample has to be obtained 
through the catheter port.  
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DIAGNOSIS 
 Examination of urine specimens for bacteriuria and leukocyturia are the 
primary laboratory investigations in suspected UTI. 
 
 Kass suggested that a threshold of ≥10⁵ bacteria per mL of urine reliably 
distinguished contaminated specimens from true bacteriuria in asymptomatic 
women, and accurately diagnosed women with acute pyelonephritis. Many 
clinicians subsequently adopted this single criterion to diagnose cystitis, although 
Kass had not, in fact, studied women with lower tract symptoms102.  Later, it has 
become apparent that cystitis with significant bacteriuria and cystitis with lower 
bacterial counts have a similar pathogenesis and may represent different stages of 
the same disease103,104. Approximately 40% of women who experience symptoms 
of cystitis have midstream urine cultures containing less than 10⁵ bacteria per 
ml102,105.  
 
 Nowadays, bacterial counts of 10⁴ or sometimes even 10³` CFU per ml, 
depending of the infecting microorganism, are regarded as significant in patients 
with clinical UTI symptoms. Therefore, the number of bacteria in urine must be 
interpreted in a complex view together with other laboratory tests and in the 
whole clinical context. Another laboratory sign of UTI is leukocyturia or 
pyuria106. The finding of pyuria is unfortunately not specific for urethritis and 
cystitis. Both systemic inflammation and asymptomatic bacteriuria may be 
accompanied by the presence of leukocytes in urine. Despite its limitations, pyuria 
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together with other tests serves as one of the indications of infection of the urinary 
tract107.  
 
Urine Culture 
 Conventional microbiologic quantification of bacteriuria is performed by 
inoculating a predefined urine volume, mostly1 or 10 μl, onto appropriate agar 
plates, incubating at 37°C overnight, then identifying the bacterial species and 
estimating the number of bacterial colonies108.  Antimicrobial susceptibility 
testing can be performed by subculturing from bacterial colonies. 
 
 Matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF MS) is a novel technique for rapid identification of 
bacterial pathogens, possibly also directly from infected urine. Although it gives 
high accuracy, conventional culture is still needed for bacterial susceptibility 
testing108. 
 
 Another way of monitoring bacterial growth, especially in the outpatient 
clinical settings, is the dip slide test. The dip slide consists of a plastic paddle with 
culture agar on each side that is immersed in urine and then incubated at 37°C 
overnight. The method allows semi quantitative measurements; however, the 
accuracy is limited, mainly because of the relatively high inoculums and the small 
agar surfaces. There are several drawbacks with the method, one being the 
absence of antibiotic susceptibility testing. Another limitation is the risk of over-
interpretation of mixed bacterial cultures, especially gram-negative bacteria and, 
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conversely, the risk of missing fastidious bacterial growth like Group B 
Streptococci109,110.  
 
Microscopic Examination of Urine 
 Urine can be examined microscopically for the presence of bacteria and 
leukocytes. Microscopic examination is simple and faster than urine culture. The 
Gram staining is useful both for analysis of bacterial type, Gram-negatives or- 
positives, morphology, rod or cocci, as well as for quantitative analysis. The 
presence of one or more bacteria per oil immersion field in uncentrifuged urine 
correlates with ≥10⁵ bacteria per ml on culture with a sensitivity and specificity 
over 90%111. However, this method does not detect low count infections, nor does 
it give possibility for species identification or antibiotic resistance. 
 
 More than 95% of patients with symptomatic UTIs have significant 
leukocyturia112. However, pyuria is also found in several other diseases not related 
to UTI. Because examination of centrifuged urine sediment is not reproducible, 
quantitative analysis of a fresh, uncentrifuged specimen of urine is 
recommended106.  The most common method is counting under the microscope 
using a hemocytometer chamber. A count of 10 or more leukocytes per ml is 
considered abnormal. Most women with symptomatic lower UTI have more than 
60 leukocytes per ml113. Leukocyturia must be carefully evaluated together with 
other symptoms and signs because it lacks specificity for symptomatic UTIs. 
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Rapid Diagnostic Tests 
 Several methods are being used for the rapid detection of bacteriuria and 
leukocyturia. Such methods may be very useful in a clinical setting when a fast 
diagnosis is essential. Optimally, rapid tests have low cost, high sensitivity, and 
high specificity. Therefore, they are useful as screening methods for groups at 
risk, such as pregnant women. Moreover, in the laboratory these tests may also 
help select which specimens require further microbiologic investigation. 
 
 Two biochemical tests have been devised: the nitrite and leukocyte esterase 
test. 
The nitrite test is based on the bacteria’s ability to reduce nitrate to nitrite. It is 
rapid to perform , evaluate and easy to interpret114,115. A test strip is immersed in 
urine and a color change is observed within 2 minutes, if positive. The test has 
high specificity, but low sensitivity, which implies that positive results indicate 
prevalence of bacteria, whereas negative results do not rule out bacteriuria 
because high bacterial concentrations are needed.  
 
 Likewise, some common uropathogenic bacteria will not be positive in the 
test. S.saprophyticus and Enterococci do not reduce nitrate to nitrite and 
Pseudomonas reduce nitrite further to ammonia and nitrogen—therefore, none of 
these bacteria will be positive. False-positive results can be obtained after having 
eaten phenazopyridine, whereas high levels of vitamin C can give false-negative 
test results.  
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 The Leukocyte esterase test is a simple and rapid test for leukocytes116. It 
has high specificity and sensitivity and gives similar results as microscopy of 
urine sediment. When granulocytes are available, the test strip rapidly turns purple 
with intensity corresponding to the leukocyte concentration. It is important to 
remember that negative results in either or both tests do not exclude bacteriuria 
and that especially a positive leukocyte esterase test can be due to reasons other 
than bacterial infection. 
 
TREATMENT 
 Safe, empiric antibiotic choices in pregnancy for UTI include 
trimethoprim-sulfamethoxazole 160/800 mg twice daily, nitrofurantoin 100mg 
twice daily, and cephalexin 250-500mg four times daily117.  Current guidelines 
support the use of a 3-day regimen in healthy women117  or a 7-day regimen to 
increase the likelihood of definitive cure in women with comorbidities118.  
Successful treatment must also be assured by the acquisition of a negative follow-
up urine culture after completion of the antibiotic regimen and periodic screening 
throughout the remainder of the pregnancy117. 
  
Materials & Methods 
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MATERIALS AND METHODS 
 
Study place: 
 The study was conducted at the Institute of Obstetrics and Gynaecology, 
Egmore in association with Institute of Microbiology ,Madras Medical College.  
 
Study duration: 
 One year between March 2017 to February 2018 
 
Study design: 
 Prospective, Cross sectional study. 
 
Ethical consideration 
 Approval from the Institutional Ethics committee was obtained before 
commencement of the study. Informed consent was obtained from all the patients 
who participated in the study. 
 
Statistical analysis 
 Statistical analysis were carried out using Statistical packages for social 
sciences (SPSS). The proportional data of this cross sectional study were analyzed 
using Pearson’s Chi Square analysis test. 
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Study population: 
Inclusion criteria: 
 Antenatal patients presenting with one or more of following  symptoms 
were  included in  the study : 
• Increased Vaginal discharge with foul smell 
• Lower abdominal pain  
• Itching or irritation in vagina 
• Pain during sexual intercourse 
• Dysuria  
• Frequent urination with urgency or leaking of urine 
• Burning sensation during urination 
• Fever with Chills & rigor 
 
Exclusion Criteria: 
• Patients on antimicrobial drugs 
• Patients with Placenta previa 
 
SAMPLE COLLECTION 
 A total of 2 high vaginal swabs were taken from each patient using sterile 
cotton tipped polyester (Himedia) swabs and a 5ml of clean catch midstream urine 
sample were collected in a sterile universal container. 
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HIGH VAGINAL SWAB COLLECTION : 
 After obtaining written informed consent from the patients, a detailed 
clinical and personal history  was taken from the patients. 
 
 Specimen collection was done in a well-lighted room. Patients were asked 
to lie on the examination table in lithotomy position, procedure was explained to 
the patient and after wearing sterile gloves, speculum was inserted into the vagina. 
The nature, colour, amount and consistency of the discharge were noted. The 
swabs were  inserted into the vagina and the discharge was collected from the 
posterior and lateral fornix.  
 
URINE SAMPLE COLLECTION: 
 Urine sample must be collected in Universal container. Clean the area 
around urethral opening with soap and clean water then rinse, dry the area with a 
sterile guazepad ; Hold the labia apart and collect midstream voided urine. For 
patients with an indwelling urinary catheter the urine sample has to be obtained 
through the catheter port . 
 
THE SCREENING FOR BACTERIAL VAGINOSIS: 
 This  was done based on Amsel’s criteria and Nugent’s scoring . 
 
AMSEL’S CRITERIA 
 It includes homogeneous vaginal discharge, pH of the vagina being > 4.5, 
the presence of clue cells in wet mount of the vaginal discharge and a positive 
whiff test. 
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According to Amsel, if 3 of the 4 criteria are positive, the patient has bacterial 
vaginosis. 
 
 Vaginal pH determination: This was done by dipping pH paper into the 
secretions pooled in the posterior fornix of vagina and compare the color 
change with a standardized colorimetric reference chart to estimate the actual 
vaginal pH . 
 Whiff test: The secretion from the swab was mixed with a drop of 10% KOH 
on a clean glass slide. An intense, putrid, fishy odour indicates positive 
reaction. 
 Wet mount preparation: Examined for presence of clue cells and motile 
flagellates of  Trichomonas vaginalis. 
 
1. Presence of Clue cells: The secretion from the swab was used to prepare a wet 
mount by mixing the secretions with a drop of normal saline on a clean grease 
free glass slide ;a cover slip was placed on it. Slide was observed under 10 x & 
40 x magnifications within 10 mins. 
 
The vaginal epithelial cells which were coated with coccobacillary organisms 
so that their edges which normally have a sharply defined cell border became 
indistinct or stippled were considered as the clue cells. Clue cells are 
characteristic feature of BV. If the clue cells constitute 20% or more of the 
epithelial cells in the high power field it was considered as positive. The clue 
cells were  also seen in Gram stained smear from HVS. 
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2. Presence of motile flagellates of Trichomonas vaginalis  :  If wet mount     
shows presence of motile flagellates then high vaginal swab was  cultured 
on to  Diamonds media. 
 
NUGENT’S CRITERIA 
 The vaginal discharge was smeared on clean glass slides, air dried, heat 
fixed and stained by Gram’s staining.  
 
 In this criterion, each Gram-stained smear was evaluated for the following 
morphotypes under oil immersion objective (l00x) by using the following scheme: 
 
Large gram-positive rods: Lactobacillus morphotype. 
Small gram-negative rods: Gardnerellamorphotype. 
Small gram variable rods: Bacteroidesmorphotype. 
Curved gram variable rods: Mobilincus morphology. 
 
The Nugent scoring system for diagnosis of bacterial vaginosis 
Score 
Lactobacillus 
Morphotype 
per field 
Gardnerella 
Morphotype 
per field 
Curved Bacteria 
(Mobiluncus) 
perField 
0 >30 0 0 
1 5-30 <1 <1-4 
2 1-4 1-4 >5 
3 <1 5-30 - 
4 0 >30 - 
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Score: 
• 0-3 = Normal/No BV 
• 4-6 = Intermediate 
• 7-10 = Bacterial vaginosis 
 
HVS AND URINE  SPECIMEN PROCESSING : 
 The high vaginal swab was used for aerobic bacterial and fungal culture. 
The samples were inoculated onto Mac conkey agar, Blood agar and Sabouraud 
dextrose agar. 
 
 Urine samples were inoculated on CLED agar. Semi quantitative culture 
was done  by standard loop method. 
 
 STANDARD LOOP METHOD: The urine specimen was mixed 
thoroughly before plating. The plates can be inoculated using  a calibrated loop to 
deliver a known volume, 0.01 ml of urine to the surface of CLED agar plate.  
 
 Once plated cultures are incubated overnight at 35° C for  24 hours to 
detect the uropathogens.                         
 
 No of Colony Forming Units /ml = no. of colonies X100 (4mm loop 
holding volume of 0.01ml was used) 
 
 A count of ≥105 colony forming units /ml of urine specimen was 
considered significant . 
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 The figure given below shows method for streaking with a calibrated loop 
to produce isolated colonies and countable colony forming units. 
 
 
 
IDENTIFICATION OF AEROBIC BACTERIAL ISOLATES: 
 Isolates from high vaginal swab and urine specimen were identified based 
on the following identification tests 
 
Identification of isolates of Staphylococcus aureus was based on following 
characteristics2: 
1. Colony morphology: 
On 5% sheep blood Agar Plate (BAP)- white opaque colonies with a Zone of  
β-hemolysis is seen. 
On MacConkeyagar (MAC)-Small lactose fermenting opaque colonies . 
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2. The isolates were subjected to preliminary test like  Gram stain, catalase test 
and coagulase test (both Slide and Tube method). 
3. The isolates which were Gram positive cocci in clusters, catalase positive, 
coagulase test positive (both Slide and Tube method) were subjected to 
biochemical reactions for further confirmation. 
4. The biochemical reactions : Fermentative pattern on Hugh-Leifson’s oxidation 
fermentation media, urea hydrolysis test was positive and mannitol was 
fermented with gas production. 
 
Identification of isolates of Staphylococcus epidermidis was based on following 
characteristics2: 
1. Colony morphology: 
On 5% sheep blood Agar Plate (BAP) -non haemolytic white opaque colonies 
hemolysis is seen. 
On MacConkey agar (MAC)-Small lactose fermenting opaque colonies. 
2. The isolates were subjected to preliminary test like  Gram stain, catalase test 
and Coagulase test (both Slide and Tube method). 
3. The isolates which were Gram positive cocci in clusters, catalase positive, 
coagulase test negative  (both Slide and Tube method) were subjected to 
biochemical reactions for further confirmation. 
4. The biochemical reactions : Fermentative pattern on Hugh-Leifson’s oxidation 
fermentation media, urea hydrolysis test was positive and mannitol was not 
fermented. 
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5. The isolate was sensitive to Novobiocin(30μg) and resistant to Polymyxin 
B(300IU). 
 
Identification of isolates of Streptococcus agalactiae was based on following 
characteristics2: 
1. Colony morphology: 
On 5% Blood Agar Plate (BAP)- β haemolytic greyish large (2mm) colonies. 
On MacConkey agar(MAC)-No growth. 
2. The isolates were subjected to preliminary test like  Gram stain and catalase 
test.  
3. The isolates which were Gram positive cocci in pairs, short chains and catalase  
negative were subjected to biochemical reactions for further confirmation. 
4. The biochemical reactions : Bile aesculin hydrolysis test was negative and 
Hippurate hydrolysis positive  
5.  CAMP test positive: when GBS is streaked on BAP perpendicular to S.aureus,  
an enhanced arrow head shaped hemolysis is produced at their junction, 
pointing towards GBS streak line. 
6. The isolate was resistant to Bacitracin(0.04U) and Cotrimoxazole 
(1.25/23.75µg). 
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Identification of isolates of Enterococcus faecalis was based on following 
characteristics2: 
1. Colony morphology  
On 5% Blood Agar Plate(BAP) - Tiny Translucent  non haemolytic colonies.  
On MacConkey agar(MAC)-Small Magenta pink (Lactose 
Fermenting)colonies  
2. The isolates were subjected to preliminary test like  Gram stain and catalase 
test.  
3. The isolates which were Gram positive oval cocci in pairs, short chains and 
catalase  negative were subjected to biochemical reactions for further 
confirmation. 
4. The biochemical reactions : Bile aesculin hydrolysis was positive, arginine 
was dihydrolysed, and arabinose was not fermented. 
5. The  isolate showed positive heat tolerance test at 60ºC and growth in 6.5% 
Sodium chloride. 
 
Identification of isolates of family Enterobacteriaceae was based on the 
following characteristics2: 
PROPERTIES E.coli Klebsiellaspp Proteus spp 
 
Colony 
Morphology 
MAC 
Flat lactose 
fermenting 
colonies 
Large  Mucoid 
lactose 
fermenting 
colonies 
Non lactose 
fermenting 
colonies 
BAP GWC GWC GWC with swarming 
Gram stain GNB Short plump GNB Pleomorphic GNB 
Catalase + + + 
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Oxidase - - - 
Motility Motile Non motile Motile 
Nitrate reduction Positive Positive Positive 
Hugh-Leifson’sOf 
test Fermentative Fermentative Fermentative 
Indole Produced 
K.oxytoca-
produced 
K.pneumoniae-
notProduced 
P.vulgaris-
produced 
P.mirabilis-not 
Produced 
Methyl red test Positive Negative Positive 
Voges-proskauer 
test Negative Positive Negative 
Citrate utilisation 
test Negative Positive Variable 
Urea hydrolysis test Negative Positive Positive 
Triple sugar iron 
agar 
Acid slant/Acid 
butt with gas 
without H2S 
Acid slant/Acid 
butt with gas 
without H2S 
Alkaline slant/Acid 
butt with abundant 
H2S 
Phenyl pyruvic acid 
test Negative Negative Positive 
Lysine 
decarboxylation test Positive Positive Negative 
Ornithine 
decarboxylation test Variable Negative 
P.vulgaris-
Negative 
P.mirabilis-Positive 
 
Identification of isolates ofAcinetobacter baumannii was based on following 
characteristics2: 
1. Colony  morphology  
On MacConkey agar(MAC)-Lactose non- fermenting pale pink colonies  
On 5% sheep blood agar plate(BAP) –small ,circular ,convex smooth colonies 
with or without hemolysis. 
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2. The isolates were subjected to preliminary test like  Gram stain, catalase test, 
oxidase test and motility by hanging drop method. 
3. The isolates which were Gram negative coccobacilli ,catalase positive, oxidase 
negative and non motile were subjected to biochemical reactions for further 
confirmation. 
4. The biochemical reactions : Nitrate not reduced , oxidative pattern on Hugh-
Leifson’s oxidation fermentation media, indole not produced, Citrate  utilised, 
urea not hydrolysed, triple sugar iron agar showed alkaline slant/alkaline  butt 
without gas or H2S production and 10% OF lactose was fermented. 
5. The  isolate showed positive growth at 42ºC.. 
 
Identification of isolates of Pseudomonas aeruginosa was based on following 
characteristics2: 
1. Colony  morphology 
On MacConkey agar (MAC)-Large spreading lactose non- fermenting colonies  
On 5%sheep blood agar plate-spreading and flat colonies with serrated edges; 
with or without hemolysis. 
2. The isolates were subjected to preliminary test like  Gram stain, catalase test, 
oxidase test and motility by hanging drop method. 
3. The isolates which were Gram negative slender bacilli ,catalase positive, 
oxidase positive and motile were subjected to biochemical reactions for further 
confirmation. 
4. The biochemical reactions : Nitrate reduced , oxidative pattern on Hugh-
Leifson’s oxidation fermentation media, indole not produced, Citrate utilised, 
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urea not hydrolysed, triple sugar iron agar showed alkaline slant/alkaline  butt 
without gas or H2S production and arginine was dihydrolysed. 
5. The  isolate showed positive growth at 42ºC.. 
 
ANTIBIOTIC SUSCEPTIBILITY TESTING 
Disc Diffusion Method 
 Antibiotic susceptibility testing of the isolated organisms was done on Mueller 
Hinton Agar(MHA) plates by Kirby Bauer disc diffusion method as per CLSI 
document M100,28thedition.The antibiotic discs were obtained from HiMedia 
Laboratories Private limited, Mumbai. 
 
Zone Diameter Interpretive Standards for Staphylococcus species119 
Antimicrobial 
Agent 
(Disc content) 
Zone Diameter Interpretive Criteria (nearest 
whole mm) 
Sensitive Intermediate Resistant 
PEN(10 U) ≥ 29 - ≤ 28 
COT(1.25/23.75 µg) ≥16 11-15 ≤ 10 
TET(30 µg) ≥19 15-18 ≤ 14 
CIP(5µg) ≥21 16-20 ≤ 15 
ERY(15 µg) ≥23 14-22 ≤13 
CK(30 µg) ≥18 13-17 ≤12 
LZ(30 µg) ≥21 - ≤ 20 
NIT(300 µg) ≥17 15-16 ≤ 14 
 
Nitrofurantoin (NIT)was included for testing and reporting  urinary isolates only. 
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Zone Diameter Interpretive Standards for β haemolytic Streptococcus 
species119 
Antimicrobial 
Agent 
(Disc content) 
Zone Diameter Interpretive Criteria  
(nearest whole mm) 
Sensitive Intermediate Resistant 
PEN (10U) ≥ 24 - - 
CTX(30 µg) ≥24 - - 
VAN(30 µg) ≥17 - - 
ERY(15 µg) ≥21 16-20 ≤ 15 
CK(30 µg) ≥21 18-20 ≤ 17 
 
Zone Diameter Interpretive Standards for Enterococcus faecalis119 
Antimicrobial 
Agent 
(Disc content) 
Zone Diameter Interpretive Criteria  
(nearest whole mm) 
Sensitive Intermediate Resistant 
PEN(10 U) ≥ 15 - ≤ 14 
NOR(10 µg) ≥17 13-16 ≤ 12 
TET(30 µg) 
 ≥19 15-18 ≤ 14 
CIP(5µg) 
 ≥21 16-20 ≤ 15 
NIT(300µg) ≥17 15-16 ≤ 14 
HLG(120 µg) ≥10 7-9 ≤ 6 
 
 Nitrofurantoin(NIT),Tetracycline(TET),ciprofloxacin(CIP) was included 
for testing and reporting  urinary isolates only. Although Enterococci are often 
tolerant to β lactams and inherently resistant to aminoglycosides synergistic 
bactericidal activity results only at high concentration of  gentamicin .Hence high 
level gentamicin (HLG) is used. 
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Zone Diameter Interpretive Standards for Enterobacteriaceae119 
   Antimicrobial agent 
(Disc content) 
Zone Diameter Interpretive Criteria 
 (nearest whole mm) 
Sensitive Intermediate Resistant 
AK(30µg) ≥ 17 15-16 ≤ 14 
GM(10 µg) ≥15 13-14 ≤ 12 
COT(1.25/23.75 µg) ≥16 11-15 ≤ 10 
CIP(5 µg) ≥21 16-20 ≤ 15 
CTX(30 µg) ≥26 23-25 ≤ 22 
TET(30 µg) ≥15 12-14 ≤ 11 
NOR(10 µg) ≥17 13-16 ≤ 12 
PT (100/10 µg) ≥21 18-20 ≤ 17 
IMP (10 µg) ≥23 20-22 ≤ 19 
NIT (300 µg) ≥17 15-16 ≤ 14 
Nitrofurantoin(NIT) was included for testing and reporting  urinary isolates only. 
Zone Diameter Interpretive Standards for Gram Negative Non-Fermenter 
Bacteria119 
Antimicrobial 
Agent 
(Disc content) 
Gram Negative 
Bacilli 
Zone Diameter Interpretive 
Criteria(nearest whole mm) 
Sensitive Intermediate Resistant 
GM(10 µg) P.aeruginosa and  A. baumannii ≥15 13-14 ≤ 12 
COT(1.25/23.75 µg) A.baumannii ≥16 11-15 ≤ 10 
CIP(5 µg) P.aeruginosa and  A. baumannii ≥21 16-20 ≤ 15 
CAZ(30 µg) P.aeruginosa and  A. baumannii ≥18 15-17 ≤ 14 
TET (30 µg) A. baumannii ≥15 12-14 ≤ 11 
NOR(10 µg) P. aeruginosa ≥17 13-16 ≤ 12 
PT(100/10 µg) 
A.baumannii ≥21 18-20 ≤ 17 
P. aeruginosa ≥21 15-20 ≤ 14 
IMP(10 µg) 
P. aeruginosa ≥19 16-18 ≤ 15 
A.baumannii ≥22 19-21 ≤ 18 
 
Tetracycline (TET) was included for testing and reporting  urinary isolates only. 
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DETECTION OF ANTIMICROBIAL RESISTANCE MECHANISMS: 
Detection of  Methicillin Resistance in Staphylococcus aureus  by using   
Disc diffusion method119 : 
 Inoculum preparation : 0.5 Macfarland turbidity standardised inoculum 
of S.aureus from blood agar plate was used . 
 Disk required :cefoxitin 30 µg disk. 
 Medium used: Mueller –Hinton agar  
 QC Recommended: S.aureus ATCC 25923 
 
Test procedure: 
 The inoculum is swabbed on to the surface of  MHA in three dimension 
and  cefoxitin disk is placed and incubated for16-18 hrs  at 33 °c- 35 ° c.  
 
Result is interpreted if the zone size  ≤ 21 mm = mecA positive   and  
                                                          ≥ 22 mm = mecA negative. 
 
 Cefoxitin is used as a surrogate marker  formec-A mediated oxacillin 
resistance. Isolates that test as mec A positive shoud be reported as oxacillin 
[methicillin] resistant  strains. 
 
E- test for vancomycin resistance detection : 
 It is a double ended  MIC graded paper  E strip [ EZY MIC TTM STRIP ] 
contain vancomycin and teicoplanin on a single strip in a concentration gradient 
manner.The upper half is coated with vancomycin concentration graded tapering 
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downwards and capable of showing MIC range of 0.5 to 32 µg/ml where as the 
lower half is coated with teicoplanin drug concentration in reverse direction to 
show MIC in range  of 0.5 to 32 µg/ml . 
 
 Inoculum preparation : from overnight growth on BAP , standardized to 
0.5 McFarland 
 Medium used : BHI agar plate  
 
Test Procedure:   
 The BHI plate was streaked 3 times with the inoculum rotating the plate 
approximately 60ºc each time to ensure an even distribution of inoculums and 
then the double ended E strip was kept on agar and incubated at35°c for 24 hrs 
 
Interpretation  : 
 Read the MIC value where the  edge of inhibition ellipse   intersect the 
side  of the E strip.     
Organism 
E strip  MIC interpretive criteria    µg /ml [clsi] 
Sensitive Intermediate Resistance 
Staphylococcus aureus ≤2 4-8 ≥16 
 
ESBL Detection in  Escherichia coli,Klebsiella species and Proteus species119: 
Phenotypic screening methods: 
 Isolates were subjected to ESBL screening test using cefotaxime 
(30μg,zone size≤ 27mm) and ceftazidime (30μg, zone size ≤ 22mm) discs. 
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ESBL Detection by CLSI phenotypic confirmatory method: 
 Lawn culture of the test isolates was made as for disc diffusion procedure. 
cefotaxime(30μg), Cefotaxime clavulanic acid disc (30/10μg),and 
ceftazidime(30μg ) Ceftazidime clavulanic acid disc (30/10μg) (Himedia)were 
placed with in 20-24mm on the surface of the plate.The test isolates were 
considered to produce ESBL if the zone size around the beta lactamase inhibitor 
combination disc was increased by ≥ 5 mm than without the beta lactam inhibitor. 
The test was performed with appropriate controls. 
 
Quality control: 
 Positive control  - K.pneumoniae ATCC 700603 
 Negative control  - E.coli ATCC 25922 
 
IDENTIFICATION OF CANDIDA 
 Candida isolates from high vaginal swab and urine specimen were 
identified based on the following identification tests 
Growth on SDA: 
 The colonies appear cream colored ,smooth and pasty. 
Gram stain morphology: 
 Gram positive budding yeast cells with or without pseudohyphae. 
Germ tube test : 
 Germ tube test is used for presumptive identification of Candida albicans. 
It is a rapid screening test where the production of germ tubes within two hours in 
contact with  the serum is considered as indicative of Candida albicans. 
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Procedure: 
1. The test was done with a fresh growth from a pure culture. 
2. A very light suspension of the test organism was inoculated in 0.5ml of the 
serum (pooled human serum). The optimum inoculums was 10⁵-10⁶cells  
per ml. 
3. Incubation was done at 37ºC for  two hours. 
4. One drop of incubated serum was placed on a slide with a cover slip and 
observed under the microscope for production of Germ tubes. 
5. Germ tubes represent initiation of hyphal growth, arising directly from the 
yeast cell. They have parallel walls at their point of origin and are not 
constricted. 
6. A positive record was taken if 30% of cells showed germ tube production.   
 
Morphology on CHROM agar Medium 130: 
 It is selective and differential type of chromogenic medium, which is useful 
for identification of various Candida species . Due to chromogenic substrate in the 
medium, the colony morphology and color have been well defined when it is used 
to isolate the yeasts. The CHROM agar candida shows following colors of 
colonies after incubation at 30ºc for a period of 48 to 72 hrs:   
 
 C.albicans : Light green , C.dubliniensis :Dark green ,C.glabrata :Pink to 
purple , C.krusei :Pink , C.parapsilosis :Cream to pale pink , C.tropicalis :Blue 
with pink halo. 
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Sugar fermentation reactions for Candida species130: 
 A liquid medium containing peptone (1%),sodium chloride 
(0.5%),Andrade’s indicator(0.005%) was prepared and sterilised by autoclaving at 
120 ºc for 15 min at 15 pounds pressure .Filter sterilised sugar was added at a 
concentration of 2% to the medium. It was poured into sterile test tubes along 
with Durham’s tube. Each broth was inoculated with 0.1ml of heavy inoculums of 
yeast grown on sugar free media. The tubes were incubated at 25 ºc upto 1 week. 
Every 48 hrs the tubes were examined for the production of acid (yellow color) 
and gas (in Durham’s tube).Production of acid and gas in tube was taken as 
positive test.  
SUGAR FERMENTATION TEST: 
 
Candida species Glucose Maltose Sucrose Lactose 
C.albicans AG AG - - 
C.troplicalis AG AG AG - 
C.kefyer AG AG AG - 
C.guilliermondii AG - AG - 
C.parapsilosis AG - - - 
C.krusei AG - - - 
C.glabrata AG - - - 
                             A=Acid production , G=Gas production 
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Sugar assimilation test for Candida species130: 
 Based on the utilization of different carbohydrates Candida species can be 
identified.  
 
 Three generation of the test organism is done on nutrient agar slope. Add 
2ml saline to 3rd generation slope, wash and make suspension. Transfer 2ml of 
yeast suspension into another sterile test tube containing 1.5ml of yeast nitrogen 
base (YNB). Add this into 13.5ml of molten and cooled (40-45 ºC ) plain agar. 
Twirl and pour into sterile petri dish which is prelabelled with 20 % sugars and 
allow it to solidify . Place the disc containing sugars in the appropriately marked 
area and incubate at 25 ºc. Growth around the disc was taken as assimilation of  
the sugar. 
SUGAR ASSIMILATION TEST: 
Candida spp. Glu Mal Suc Lac Cel Gal Tre Raf Mel Xyl Ino Dul 
C.albicans + + + + + + + - - + - - 
C.tropicalis + + + - + + + - - + - - 
C.kefyer + - + + + + - + - + - - 
C.parapsilosis + + + - - + + - - + - - 
C.guilliermondii + + + - + + + + + + - + 
C.krusei + - - - - - - - - + - - 
C.glabrata + - - - - - + - - + - + 
 
Note:Glu=Glucose, Mal=Maltose, Suc=Sucrose, Lac=Lactose, Cel=Cellobiose, 
Gal=Galactose, Tre=Trehalose, Raf=Raffinose, Mel=Melibiose, Xyl=Xylose, 
Ino=Inositol, Dul=Dulcitol , +=positive reaction ,- = negative reaction. 
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METHOD FOR ANTIFUNGAL DISK DIFFUSION SUSCEPTIBILITY 
TESTING FOR YEAST(CLSI M44-A2) 
 
REAGENTS THAT WERE USED FOR DISK DIFFUSION TEST 
 Mueller Hinton Agar +2% glucose and 0.5μg/ml Methylene blue 
dye(GMB)medium. 
 
PROCEDURE FOR PERFORMING THE DISK DIFFUSION TEST 
Steps for preparation of the inoculums are as follows: 
1. All organisms were subcultured on Sabourauds dextrose agar. 
2. Inoculum was prepared by picking up five distinct colonies and suspended 
in 5ml of sterile saline. 
3. The resulting suspension was matched with 0.5 McFarland standard at 
530nm wavelength.  
 
Inoculation of test plates 
1. After 15 mins of suspension preparation a swab is dipped into the 
suspension and plated onto the dried surface of Mueller Hinton + GMB 
agar plates 
2. The plate was streaked 3 times rotating the plate approximately 60ºc each 
time to ensure an even distribution of inoculums 
3. Drug impregnated disks were applied on the plate after 15 mins. 
4. The plates were read after 24 hrs of incubation. 
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Zone Diameter Interpretative Standards 
Susceptible (S): 
 The susceptibility category implies that an infection an infection due to the 
strain can be appropriately treated with the dose of antimicrobial agent 
recommended for that type of infection . 
 
Susceptible –Dose Dependent(SDD): 
 The Susceptible dose dependent category includes isolates with 
antimicrobial agent MICs that approach usually attainable blood and tissue levels 
and for which response rates may be lower than for susceptible isolate. 
 
Resistant(R): 
 The resistant strains are those that are not inhibited by the usually 
achievable concentration of the agent with normal dosage schedules. 
 
Zone diameter interpretive standards for Candida species 
Antifungal 
agent Disc content 
Zone diameter interpretation 
R SDD S 
Fluconazole 25μg ≤14 15-18 ≥19 
Voriconazole 1μg ≤13 14-16 ≥17 
 
  
Results 
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RESULTS 
 
 A total of 200 antenatal patients were included in this study out of which 
33 patients  were from  out patient department and others were from inpatient 
department of Institute of Obstetrics and gynaecology, Egmore. The study was 
done between March 2017 to February 2018 . The results obtained from the study 
are as follows. 
 
TABLE 1:DISTRIBUTION OF AGE (IN YEARS) OF PATIENTS 
INCLUDED IN THE STUDY (n=200) 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
11-15 2 0.8 % 
16-20 22 8.3 % 
21-25 89 33.5% 
26-30 59 22.2% 
31-35 21 7.9% 
36-40 6 2.3% 
41-45 1 0.4% 
TOTAL 200 100% 
 
 The above table shows distribution of age in years of the antenatal patients 
who were included in the study.The maximum number of patients were in the age 
group between 21-25 years (33.5%) followed by 26-30 years (22.2%). 
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FIGURE 1 
 
 
TABLE 2:DISTRIBUTION OF PRESENTING COMPLAINTS OF THE 
PATIENTS 
 
SYMPTOMS NO OF PATIENTS PERCENTAGE 
DISCHARGE 155 77.5% 
FOUL SMELL 30 15% 
LOWER ABDOMINAL PAIN 65 32.5% 
BURNING MICTURITION 42 21% 
VAGINAL DISCOMFORT 25 12.5% 
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FIGURE 2 
 
 
TABLE 3 :AGE WISE DISTRIBUTION OF THE PRESENTING 
COMPLAINTS 
 
AGE GROUP 11-15 years 
16-20 
Years 
21-25 
years 
26-30 
years 
31-35 
years 
36-40 
years 
41-45 
years TOTAL % 
DISCHARGE 2 (1.3%) 
16 
(10.3%) 
64 
(41.3%) 
49 
(31.6%) 
19 
(12.3%) 
4 
(2.6%) 
1 
(0.6%) 155 77.5 
FOUL SMELL 0  
3 
(10%) 
12 
(40%) 
10 
(33.3%) 
3 
(10%) 
1 
(3.3%) 
1 
(3.3%) 30 15 
LOWER 
ABDOMINAL 
PAIN 
0 9 (13.8%) 
32 
(49.2%) 
18 
(27.7%) 
3 
(4.6%) 
3 
(4.6%) 0 65 32.5 
BURNING 
MICTURITION 0 
2 
(4.8%) 
20 
(47.6%) 
16 
(38.1%) 
2 
(4.8%) 
2 
(4.8%) 0 42 21 
VAGINAL 
DISCOMFORT 0 
5 
(20%) 
9 
(36%) 
8 
(32%) 
2 
(8%) 
1 
(4%) 0 25 12.5 
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 The above table shows that the commonest symptom that was presented by 
the patients included in the study was vaginal discharge. Vaginal discharge was 
the predominant complaint in 77.5% of the total patients and in 41.3% of patients 
in 21-25 years of age. The next common complaint presented was lower 
abdominal pain which was seen in 32.5% of patients and in 49.2% of patients in 
21-25 years of age. Other symptoms such as burning micturition (21%),foul smell 
(15%) and vaginal discomfort were also presented by the patients. 
 
TABLE 4 :TRIMESTER WISE DISTRIBUTION OF INFECTIOUS 
VAGINITIS 
TRIMESTER TOTAL    PATIENTS BV VVC TV POSITIVE 
Statistic  
Chi-
square 
test 
1 32(16%) 6(14.3%) 3(16%) 0 9  (13.8%) 
p-value 
>0.05 
2 99(49.5%) 19(45.2%) 12(49.5%) 0 31(47.7%) 
3 69(34.5%) 17(24.6%) 8(34.5%) 0 25(38.5%) 
Total 200 42 23 0 65 
 
 The higher rate of vaginal infection was found in 2nd  trimester of  
pregnancy 31(47.7%) followed by 3rd trimester 25( 38.5%) and then 1st trimester 
9(13.8%). However the difference was not statistically significant. (p>0.05) 
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TABLE 5 :TRIMESTER WISE DISTRIBUTION OF UTI 
TRIMESTER TOTAL    PATIENTS UTI 
Statistic Chi-
square test 
1 32(16%) 1(3.1%) 
P-value<0.05 
2 99(49.5%) 15(46.9%) 
3 69(34.5%) 16(50%) 
Total 200 32(16%) 
 
The higher rate of urinary tract  infection was found in 3rd  trimester of pregnancy 
16(50%) followed by 2nd trimester 15( 46.9%) and then 1st trimester 1(3.1%).The 
difference was statistically significant. (p<0.05) 
 
FIGURE 3 
 
 
14.3
45.2
24.6
16
49.5
34.5
3.1
46.9
50
1ST TRIMESTER 2ND TRIMESTER 3RD TRIMESTER
DISTRIBUTION OF VAGINITIS AND UTI IN DIFFERENT 
TRIMESTER OF PREGNANCY
BACTERIAL VAGINOSIS VULVOVAGINAL CANDIDIASIS UTI
 
65 
 
 
TABLE 6 :AGE WISE DISTRIBUTION OF VAGINITIS AMONG 
ANTENATAL WOMEN (n=200) 
AGE 
CATEGORY 
TOTAL 
PATIENTS 
INFECTION 
POSITIVE 
Statistic 
Chi-square 
test BV VVC BV+VVC 
11-15 2 0 0 0 0 ( 0%) 
P-
value>0.05 
16-20 22 3 (7.1%) 
2 
(8.7%) 
1 
(14.3%) 
5 
(7.6%) 
21-25 89 18 (42.9%) 
8 
(34.8%) 
2 
(28.6%) 
26 
(40%) 
26-30 59 18 (42.9%) 
10 
(43.5%) 
2 
(28.6%) 
28 
(43.1%) 
31-35 21 2 (4.8%) 
2 
(8.7%) 
1 
(14.3%) 
4 
(6.1%) 
36-40 6 1 (2.4%) 
1 
(4.3%) 
1 
(14.3%) 
2 
(3.2%) 
41-45 1 0 0 0 0 
TOTAL 200 42 23 7 65 
 
 The prevalence of infectious vaginitis in the study was found to be 
32.5%.The infection rate was high among the age group 26-30 years (43.1%) and 
least infected group was 11-15 and 41-45 years (0.0%).Mixed infection of BV and 
VVC was found in age group 21-25 and 26-30 years. Both BV and VVC were 
found high  in age group  26-30 years. However the difference was not 
statistically significant(p>0.05). 
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TABLE 7 :AGE WISE DISTRIBUTION OF UTI AMONG  
ANTENATAL WOMEN(n=200) 
AGE 
CATEGORY 
TOTAL 
PATIENTS UTI 
Statistic 
Chi-square test 
11-15 2 0  (0.0%) 
 
 
P-value<0.05 
16-20 22 2  (6.2%) 
21-25 89 11(34.4%) 
26-30 59 17(53.1%) 
31-35 21 0(0.0%) 
36-40 6 1(3.1%) 
41-45 1 1(3.1%) 
TOTAL 200 32(16%) 
 
 The UTI was predominantly seen in antenatal patients with age group 26-
30 years followed by age group 21-25 years . These two age groups had 
maximum number of patients included in the study. 
 
FIGURE 4 
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TABLE 8 :ASSOCIATION OF BACTERIAL VAGINOSIS (BV) WITH UTI 
DURING PREGNANCY(n=200) 
DIAGNOSIS UTI PRESENT 
UTI 
ABSENT TOTAL 
Statistic Chi-
square test 
BV 
PRESENT 15 27 42 
P<0.05 BV 
ABSENT 17 141 158 
TOTAL 32 168 200 
 
n=200 NO. % 
BACTERIAL VAGINOSIS PRESENT 42 21 
BACTERIAL VAGINOSIS ABSENT 158 79 
URINARY TRACT INFECTION PRESENT 32 16 
URINARY TRACT INFECTION ABSENT 168 84 
BACTERIAL VAGINOSIS ASSOCIATED WITH 
UTI  15 35.7 
UTI WITHOUT BV 17 10.7 
 
 The above table shows that BV was present in 42 antenatal patients (21%) 
and  UTI was present in 32 patients (16%). About 15 patients with BV(out of 42) 
had associated UTI. The association between BV and UTI was found to be 
statistically significant(p<0.05). 
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TABLE 9 :ASSOCIATION OF  
VULVO VAGINAL CANDIDIASIS (VVC) WITH UTI 
DIAGNOSIS UTI PRESENT UTI ABSENT TOTAL Statistic Chi-square test 
VVC 
PRESENT 4 19 23(11.5%) 
P>0.05 VVC ABSENT 28 149 177(88.5%) 
TOTAL 32 168 200 
 
 The above table shows that VVC  was present in 23 antenatal patients 
(11.5%) and  UTI was present in 32 patients (16%). About 4 patients with 
VVC(out of 23) had associated UTI. VVC associated with UTI was seen in 17.4% 
of the patients. However the association between VVC and UTI was statistically  
not significant(p>0.05). 
 
TABLE 10 :AMSEL’S CRITERIA FOR DIAGNOSIS OF BV 
S.NO VARIABLE PRESENT 
1. VAGINAL DISCHARGE 155(77.5%) 
2. CLUE CELLS 46(23%) 
3. WHIFF TEST 70(35%) 
4. pH > 4.5 132(66%) 
 
 Based on Amsel’s criteria ,35 cases were labelled to have BV. The 
predominant variable present was vaginal discharge 155(77.5%) and least 
occurring variable in patients with BV was presence of clue cells46(23%) in 
vaginal  wet mount. 
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FIGURE 5 
 
TABLE 11 :NUGENT’S SCORING FOR DIAGNOSIS OF BV 
S.NO SCORE NO. OF CASES 
1. 0-3 85(42.5%) 
2. 4-6 73(36.5%) 
3. 7-10 42(21%) 
 TOTAL 200 
 
Based on Nugent’s criteria, 42(21 %) cases were labelled to have BV.  
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FIGURE 6 
 
 
TABLE 12 :DIAGNOSIS OF BACTERIAL VAGINOSIS BY COMPARISON 
BETWEEN AMSEL’S CRITERIA AND  NUGENT’S SCORING. 
METHODS OF 
DIAGNOSIS 
DIAGNOSIS OF BV BY NUGENTS 
SCORING 
p-value Score >7 BV 
PRESENT 
(n=42) 
Score 0-6 
BV 
ABSENT 
(n=158) 
Total 
(n=200) 
AMSEL’S 
CRITERIA 
BV 
PRESENT 28 7 35  
p<0.05 BV 
ABSENT 14 151 165 
 
 In comparison with gold standard Nugent’s  criteria ,the sensitivity 
,specificity, positive predictive value and negative predictive value of Amsel’s 
criteria were 80%, 91.5%, 66.7% and 95.6% respectively. Statistical analysis 
showed that both methods could be used as a means for diagnosis of Bacterial 
vaginosis (p <0.05). 
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TABLE 13 :BACTERIAL ISOLATES DETECTED FROM HVS AND 
URINE CULTURE 
ISOLATES 
FROM HVS TOTAL MDR(%) 
ISOLATES 
FROM URINE TOTAL MDR(%) 
E.coli 13 3 (23.0) E.coli 10 5(50.0) 
K.pneumoniae 7 1 (14.2) K.pneumoniae 4 2(50.0) 
K.oxytoca 7 1 (14.2) K.oxytoca 3 0(0.0) 
P.mirabilis 3 0 (0.0) P.mirabilis 3 0(0.0) 
P.vulgaris 0 0(0.0) P.aeruginosa 2 0(0.0) 
S.aureus 7 2(28.5) S.aureus 3 1(33.3) 
S.epidermidis 2 0(0.0) E.faecalis 1 0(0.0) 
S.agalactiae 1 0(0.0) A.baumannii 1 1(100.0) 
TOTAL 40 7 TOTAL 27 9 
 
 The predominant bacteria isolated from both HVS and urine was E.coli. Of 
the isolated bacteria from HVS 28.5% of S.aureus ,23% of E.coli , 14.2% of 
K.pneumoniae and K.oxytoca were Multidrug resistant ( MDR) isolates. Also 
50% of E.coli, 50% K.pneumoniae ,33.3% of S.aureus  isolated from urine were 
MDR isolates. An isolate of A.baumannii from urine specimen was also MDR. 
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FIGURE 7 :TRIMESTER WISE DISTRIBUTION  
OF ISOLATES FROM URINE 
 
 
 
 About 2.8% of  E.coli and 1.4% K.oxytoca isolates in 2nd trimester were 
found to be ESBL producers. Candida albicans (3%) was found more common in 
2nd trimester UTI. Overall higher rate of UTI was found in 3rd trimester of 
pregnancy and the difference was statistically significant (p<0.05) 
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FIGURE 8 :TRIMESTER WISE DISTRIBUTION  
OF ISOLATES FROM HVS 
 
 
 
 The 2nd trimester of pregnancy showed maximum bacterial growth of 
28.3% followed by 3rd trimester 14.5%. however the difference was not 
statistically significant(p>0.05) 
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TABLE 14 :ANTIMICROBIAL SUSCEPTIBILITY PATTERN  
FOR URINARYISOLATES GNB: 
DRUGS 
 
 
 
 
 
ISOLATES 
GM 
10μg 
CTX 
30μg 
CEC 
30/ 
10μg 
NIT 
300μg 
NOR 
5μg 
CAZ 
30μg 
PT 
100/ 
10μg 
CIP 
5μg 
COT 
1.25 
/23.75 
Μg 
AK 
30μg 
TET 
30μg 
IMP 
10μg 
% % % % % % % % % % % % 
E.coli 
n=10 60 30 80 80 60 - 60 - - 50 100 100 
K.pneumoniae 
n=4 75 25 75 50 50 - 50 - - 50 100 100 
K.oxytoca 
n=3 100 33 100 100 100 - - - - 100 - - 
P.mirabilis 
n=3 100 100 100 * 100 - 100 33 100 - * - 
P.aeruginosa 
n=2 100 * # # 0 100 100 0 * - * 100 
A.baumannii 
n=1 0 - # - - 0 100 0 0 - 0 0 
NOTE:     * :Intrinsic resistance ,  - : Not tested   ,   #: Not applicable 
 
 
TABLE 15 :ANTIMICROBIAL SUSCEPTIBILITY PATTERN FOR 
URINARY ISOLATES GPC: 
DRUGS 
 
 
 
 
ISOLATES 
PEN 
10U 
 
(%) 
NOR 
5μg 
 
(%) 
NIT 
300μg 
 
(%) 
COT 
1.25/ 
23.75 
μg 
(%) 
CIP 
5μg 
 
(%) 
CX 
30μg 
 
(%) 
ERY 
15μg 
 
(%) 
TET 
30μg 
 
(%) 
HLG 
120μg 
 
(%) 
S.aureus 
n=3 33 - 66.6 66.6 66.6 66.6 66.6 100 # 
E.faecalis 
n=1 100 100 100 * 0 # 0 100 100 
NOTE:        *: Intrinsic resistance  ,      - : Not tested ,       #: Not applicable 
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 Among the urinary isolates cefotaxime was found to be 70% resistant 
toE.coli, 75%resistant  K.pneumoniae and 67% resistant to K.oxytoca. 
cefotaximeclavulanate was found to be 20% resistant to E.coli, and 25% resistant 
to  K.pneumoniae , 100% sensitive to  K.oxytoca and P.mirabilis. Higher 
susceptibility was seen with tetracycline(100%)  for E.coli, K.pneumoniae and 
E.faecalis. Imipenem100% sensitive for E.coli and K.pneumoniae . P. mirabilis 
was 100% sensitive to piperacillin tazobactum ,cefotaxime,cotrimoxazole, 
gentamicin and norfloxacin . P.aeruginosa was 100% sensitive to gentamicin 
,ceftazidime and piperacillin tazobactum. A.baumannii was MDR but 100% 
sensitive to piperacillin tazobactum. 
 
TABLE 16 :ANTIMICROBIAL SUSCEPTIBILITY PATTERN FOR 
VAGINAL ISOLATES GNB: 
DRUGS 
 
 
 
ISOLATES 
GM 
10μg 
 
(%) 
CTX 
30μg 
 
(%) 
CEC 
30 
/10μg 
(%) 
PT 
100/ 
10μg 
(%) 
CIP 
5μg 
 
(%) 
COT 
1.25/ 
23.75 
μg 
(%) 
AK 
30μg 
 
(%) 
TET 
30μg 
 
(%) 
IMP 
10μg 
 
(%) 
E.coli 
n=13 90 36 86 - 78.5 57 43 100 100 
K.pneumoniae 
n=7 100 57 85.7 - 100 85.7 85.7 100 100 
K.oxytoca 
n=7 85.7 42.8 71 - 57 57 71 100 100 
P.mirabilis 
n=3 100 100 100 100 100 0 100 * - 
NOTE:* :Intrinsic resistance                     - : Not tested   
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TABLE 17 :ANTIMICROBIAL SUSCEPTIBILITY PATTERN FOR 
VAGINALISOLATES GPC: 
DRUGS 
 
 
 
 
ISOLATES 
PEN 
10U 
 
 
(%) 
COT 
1.25/ 
23.75 
μg 
(%) 
CIP 
5μg 
 
 
(%) 
CX 
30μg 
 
 
(%) 
CTX 
30μg 
 
 
(%) 
ERY 
15μg 
 
 
(%) 
TET 
30μg 
 
 
(%) 
VAN 
30μg 
 
 
(%) 
CK 
30μg 
 
 
(%) 
LZ 
30μg 
 
 
(%) 
S.aureus 
n=7 43 57 71 71 # 71 71 # 100 100 
S.epidermidis 
n=2 0 100 0 100 # 100 100 # - - 
S.agalactiae 
n=1 0 0 # # 100 100 - 100 100 - 
NOTE:   - : Not tested ,       #: Not applicable 
Organism 
E strip  MIC for vancomycin 
MIC REPORT 
Staphylococcus aureus 
(MRSA) n=2 <2 Sensitive(100%) 
 
 Among the vaginal isolates Cefotaxime was found to be 64% resistant to 
E.coli, 43% resistant  K.pneumoniae and 57% resistant to K.oxytoca. Cefotaxime 
clavulanate was found to be 14% resistant to E.coli, and  K.pneumoniae and 29% 
resistant to K.oxytoca. Higher susceptibility was seen with Tetracycline(100%)  
for E.coli, Klebsiella spp  and  S.epidermidis. Imipenem100% sensitive for E.coli 
and Klebsiella spp . P. mirabilis was 100% sensitive to Piperacillin tazobactum, 
ciprofloxacin, cefotaxime, amikacin and gentamicin . 
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 S.aureus was highly susceptible to chloramphenicol (100%) and 
linezolid(100%) and least sensitive to penicillin. Two MRSA isolates had 
vancomycin  MIC in susceptible  range. S.agalactiae was 100% sensitive to 
erythromycin ,cefotaxime ,chloramphenicol and vancomycin. 
 
TABLE 18 :CANDIDA SPECIES ISOLATED FROM HVS 
CANDIDA SPECIES NO. OF ISOLATES n =23 % 
C.albicans 14 60.9 
C.glabrata 3 13 
C.tropicalis 3 13 
C.krusei 1 4.3 
C.parapsilosis 2 8.6 
 
FIGURE 9 
 
 Candida albicans(60.9%) was the commonest species isolated in this study. 
Of the non-albicans species isolated C.glabrata(13%) and C.tropicalis (13%) were 
the most common. 
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TABLE 19 :ANTIFUNGAL SUSCEPTIBILITY  PATTERN OF CANDIDA 
ISOLATES  FROM HVS SAMPLES 
       ISOLATES 
 
DRUGS 
C.albicans 
n=14 
C.glabrata 
n=3 
C.troplicalis 
n=3 
C.parapsilosis 
n=2 
Fluconazole 
(25 μg) 14 100% 1 33% 3 100% 2 100% 
Itraconazole 
(10 μg) 14 100% 1 33% 3 100% 2 100% 
Voriconazole 
(1 μg) 13 93% 0 0% 3 100% 2 100% 
Nystatin B 
(1 μg) 12 86% 2 67% 2 100% 2 100% 
 
 
DRUG 
 
 
ISOLATE 
Nystatin B susceptibility 
(1 μg) 
C.krusei 
(n=1) 100% 
 
*C.krusei is inherently resistant to azoles so tested only with Nystatin B 
 
 Candida albicans isolates were 100% sensitive to Fluconazole ,Itraconazole 
and least sensitive to Nystatin B.  
 
 Among Candida non albicans species  C.tropicalis and C.parapsilosis  
isolates were 100% sensitive to fluconazole ,itraconazole , voriconazole and 
nystatin B. C.glabrata was only 33% sensitive to fluconazole ,itraconazole and 
C.krusei was100%  sensitive to nystatin B. 
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TABLE 20 :CANDIDA SPECIES ISOLATED FROM URINE : 
CANDIDA SPECIES NO. OF ISOLATES n =5 % 
C.albicans 4 80 
C.tropicalis 1 20 
 
FIGURE 10 
 
 
 
 Candida albicans(80%) was the commonest species isolated . Only one 
non-albicans species was isolated which was identified as  C.tropicalis (20%). 
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TABLE 21 :ANTIFUNGAL SUSCEPTIBILITY  PATTERN OF CANDIDA 
ISOLATES  FROM URINE SAMPLES 
                            ISOLATES 
DRUGS 
C.albicans 
n=4 
C.troplicalis 
n=1 
Fluconazole 
(25 μg) 4 100% 1 100% 
Itraconazole 
(10 μg) 4 100% 1 100% 
Voriconazole 
(1 μg) 4 100% 1 100% 
Nystatin B 
(1 μg) 4 100% 1 100% 
 
 Candida albicans isolates were 100% sensitive to Fluconazole ,Itraconazole 
and Nystatin B and 75% sensitive to voriconazole.  
 
 C.tropicalis was 100% sensitive to fluconazole ,itraconazole , voriconazole 
and nystatin B. 
 
 Candida albicans was the commonest species among Candida isolated from 
HVS(60.9%) and urine (80%) . C.tropicalis(20%) was the only Candida non 
albicans species isolated from urine specimen  and it was also found in HVS 
(13%). C.tropicalis both from HVS and urine was 100%  sensitive to all azoles 
tested and nystatin B. Whereas Candida non albicans species inherently resistant 
to azoles (C.krusei ) was isolated from HVS culture. 
 
Discussion 
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DISCUSSION 
 
 This study was conducted in the antenatal patients  irrespective of their 
gestational age attending the Institute of obstetrics and Gynaecology. About 200 
patients who fulfilled the inclusion criteria were included in the study. 
 
 The prevalence of  infectious vaginitis among antenatal women was found 
to be 32.5%.  Similar reports were obtained in study done by Lamichnane et al18 
in Nepal on prevalance of infectious vaginitis which was found to be 40%. But 
another study by O.A.Olowe et al20 in south western Nigeria reported  prevalence 
of vaginitis to be 76% which was much higher when compared to our study. 
 
 Vaginitis was most common in the age group 26-30years(43.1%) followed 
by 21-25years(40%) which might be because these age groups  represent 
reproductively active age, having high sexual exposure .The study by Dipak 
bhargava et al120 conducted  in Nepal showed similar results of infectious vaginitis 
being most common in the age group 20-29years (56.1%).However in both of these 
studies the age of the patients in the reproductive age group does not reveal any 
significant relationship with vaginitis (p>0.05). 
 
 In our study higher rate of vaginal infection was found in 2nd trimester of 
pregnancy (47.7%). In contrast to our result study by O.A Adeyeba et al1 in 
Nigeria had higher rate of vaginal infection during 3rd trimester of pregnancy but 
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reported that gestational age has no statistical significance in distribution of 
vaginal infection (p>0.05) which was similar to our study.   
 
 Bacterial vaginosis  was the most prevalent type of vaginitis (21%) 
followed by vulvovaginal candidiasis(11.5%) and mixed infection was seen in 
only 3.5% of the patients. In concordance with our finding study by Lata et al 52in 
Lucknow showed BV in 20.5% and mixed infection in 1.5% of antenatal patients 
but in contrast  VVC was seen in only 4.5% of the patients.   
 
 For most of the bacterial diseases culture is the gold standard method for 
diagnosis ; however, culture cannot  become the gold standard for diagnosis of 
BV as the organisms which are involved in BV cannot be easily  isolated in the 
laboratory  and as normal women may also have this flora in their vagina in small 
numbers .  Alternative diagnostic methods have been developed, such as the 
polymerase chain reaction (PCR), rapid nucleic acid hybridization test and proline 
amino peptidase activity for the diagnosis of BV. However, most of these are 
expensive and their sensitivities and specificities do not offer a huge advantage 
over the classical methods. 
 
 As the prevalence of BV in developing countries like ours  are high, 
countries with limited resources have a great need for inexpensive diagnostic 
methods that are reliable and unifies clinical and microbiological parameters to 
make it more sensitive while retaining its specificity. 
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 Amsel’s and Nugent’s scoring remain the most practical, viable and 
economical options for diagnosing bacterial vaginosis, especially in developing 
countries 21,35.Therefore in this study diagnosis of BV was done based on Amsel’s 
clinical criteria and Nugent’s scoring of  vaginal smears. Amsel’s criteria detected 
35/200( 17.5 %) whereas Nugent’s score identified 42/200 (21%)patients as 
having BV as shown in Table 12. In comparison with Nugent’s criteria, the 
sensitivity, specificity, positive predictive value and negative predictive value of 
Amsel’s criteria were 80%, 91.5%, 66.7% and 95.6% respectively. Statistical 
analysis showed that both methods (Amsel’s and Nugent’s criteria) could be used 
as a means for the diagnosis of bacterial vaginosis (p<0.05) .Study by Rajeshwar 
Rao et al81 al in Hyderabad and Nawani et al121 showed similar findings to our 
results. 
 
 Vaginal discharge was the predominant complaint and the common criteria 
which were present in almost 77.5% of the patients included in the study.This was 
found to be in correlation with the study conducted by A.Agarwal et al126., who 
showed a prevalence of 84% in his study. pH was found to be greater than 4.5  in 
about 66% of patients in this study which was lesser compared to results by 
A.Agarwal et al.,(88%).Amine test was found to be positive in around 35% of 
patients in this study compared to 68% of patients in the above study.Clue cells 
were also found to be much lower (23%) in our study when compared to the 
above study(64%). A significant correlation was seen between bacterial vaginosis 
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and the occurrence of symptoms like foul smelling discharge,lower abdominal 
pain and burning micturition(p<0.05) 
 
 In this study, the overall prevalence of  Trichomonas vaginalis(TV) was  
0 % as shown in table 4.  This suggest the non-existence of relatively high rate of 
this infection among pregnant women attending Institute of obstetrics and 
Gynaecology, Egmore which could be due to improved healthy living. Similarly 
study done on prevalence of TV among pregnant women attending  Irrua 
Specialist Teaching Hospital ,Nigeria by  Ochei Kingsley Chinedum et al122 
showed  0% prevalence and study by Lata et al 52 in Lucknow also reported 0% 
prevalence  of TV . However Nourian A et al123 reported 3.3% prevalence of TV 
among pregnant population in North west Iran. 
 
 Table 5 shows the  prevalence of UTI was found to be 16% with higher 
rate of infection  found in 3rd trimester (50%) followed by 2nd trimester (46.9%) 
and the difference was found to be statistically significant(p<0.05). UTI was 
predominantly seen in age group 26-30 years followed by 21-25 years this was 
because maximum number of patients included in this study were from these age 
groups.   This finding is comparable to studies by Bandyopadhyay et al30 and 
Sabharwal31 which reported prevalence of UTI as 25.2% and 24%, respectively. 
Study by  Kant, et al 4in rural Haryana also reported that  the proportion of 
pregnant women with UTI was maximum in the third trimester similar to our 
study. This has also been shown in other studies in the past. Hence, if only one 
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time screening is affordable by the patient , then it should preferably done in the 
third trimester of pregnancy. 
 
 Table 8 shows the association of  BV with UTI during pregnancy. BV was 
present in 42 antenatal patients (21%) and  UTI was present in 32 patients (16%). 
About 15 patients with BV(out of 42) had associated UTI. BV associated with 
UTI was seen in 35.7% of the patients .The association between BV and UTI was 
found to be statistically significant (p<0.05). Previous similar  study done by Lata 
et al52 in Lucknow showed that  about 14 patients with BV(out of 41) had 
associated UTI.. Also studies by Sharamiet al. and Hillerbrandet al38. have also 
reported pregnant women with bacterial vaginosis have a significantly increased 
risk of UTI.  
 
 The association between  BV and UTI probably begins with raised vaginal  
pH because of the reduction in the number of vaginal lactobacilli. The lactobacilli 
produces lactic acid and hydrogen peroxide which are lethal to a number of 
bacterial species and also have been demonstrated to inhibit potential pathogens.  
In addition, lactobacilli produces a  number of  bacteriocins that are active against 
a wide range of bacteria and fungi. So, once the vaginal ecology is disturbed 
during BV, allowing colonization of potential uropathogens, the patient becomes 
more susceptible to UTI. 
 Sexual intercourse has an important confounding role on the association of  BV 
and UTI18. An exogenous factor in the semen creates an imbalance in vaginal 
microflora and facilitate the  development of  BV. The urethral massage during 
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the sexual activity has a facilitating role in moving the urethral colonizers into the 
bladder125. Besides the effect of BV and sexual activity on the acquisition of UTI, 
the differences in the living standards, personal hygiene ,education, socio-cultural 
practices and awareness of the individual may be the reasons for the differences 
seen in the incidence of UTI in vaginitis in different communities. 
 
 Thus considering the complications associated with untreated BV and UTI 
it might be cost effective and wise to test for infectious vaginitis in women with 
UTI and vice versa.  
 
 Table 9 shows that  about 4 patients with VVC(out of 23) had associated 
UTI. VVC associated with UTI was seen in 17.4% of the patients. However the 
association between VVC and UTI was statistically  not significant  (p>0.05).  In 
contrast to our results study done  by R Amatya et al 125showed significant 
association between vaginal candidiasis with UTI during pregnancy. 
 
 In accordance with this study, vaginal colonization by E. coli, Klebsiella 
species, Proteus species., Staphylococci and Streptococci species  during 
pregnancy has also been reported by different authors.  Increase in vaginal pH 
with raised  vascularity and estrogen content, bowel movement, cleansing habits, 
presence of hemorrhoids and use of sanitary napkins  influence the growth and 
colonization of different pathogens in vagina during pregnancy18.  In our study 
17.5% of vaginal isolates were found as MDR which includes 28.5% of  S.aureus 
and 23% of  E.coli. This which was much lesser  when compared to  study done 
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by Lamichhane et al18 in Nepal where 50%  of vaginal isolates were multi drug 
resistant organisms. Streptococcus agalactiae( Group B Streptococci β 
haemolytic, GBS) constitutes about 2.5% of total vaginal isolates in our study.The 
isolate  showed 100% susceptibility to cefotaxime, erythromycin, 
chloramphenicol and vancomycin. However study by Lamichhane et al18 and 
M.Bayó et al129 reported higher prevalence of 8.6% and 7% respectively. GBS 
infection is an important cause of neonatal morbidity and mortality. A complete 
and detailed evaluation of the vaginal microbiota with particular attention to the 
presence of potential pathogens such as GBS is a preventive strategy that can 
provide useful information to obstetricians and gynaecologist in managing the last 
days of pregnancy and delivery. 
 
 Table 13 shows the uropathogens isolated in our study which  includes 
E.coli , Klebsiella spp, Proteus spp,  A.baumannii, S.aureus and E.faecalis. About 
33% of the urinary isolates  were found MDR with 50% E.coli and K.pneumoniae 
being MDR. An isolate of A.baumannii from urine was also MDR.   
Lamichhaneet al18 reported similar profile of uropathogens with 56% MDR 
isolates. The higher rate of MDR among uropathogens may be because of 
repeated and irrational use of antibiotics which is especially true for developing 
countries where antibiotics are irrationally prescribed not only by the medical 
practitioners but the antibiotics are also purchased directly from the pharmacist  
without any prescription. Therefore the empirical treatment of UTIs have become 
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more difficult and choice of antibiotics should be based on urine culture and 
antimicrobial susceptibility testing . 
 
 Table 18 and 19 shows that Candida albicans was the commonest species 
among candida isolated from HVS(60.9%) and Urine (80%) . Similar results were 
obtained  by Holst et al19 in a study conducted in Sweden and other studies 
conducted in our country. 
 
 C.tropicalis was the only Candida non albicans species isolated from (20%) 
urine specimen  and it was also found in (13%) HVS .C.glabrata (13%), 
C.parapsilosis (8.6%) and  C.krusei (4.3% ) were the candida species isolated 
from HVS. Study by Gandhi el al127 in Gujarat showed similar finding of 
C.albicans 66 %,C.glabrata 15%, C.krusei 3%,C.parapsilosis 5% and C.tropicalis 
9.8% isolated from HVS. 
 
 Antifungal susceptibility  pattern of candida isolates  from HVS showed 
that Candida albicans isolates were 100% sensitive to Fluconazole ,Itraconazole 
and least sensitive to Nystatin B(86%). Among Candida  non albicans species  
C.tropicalis and C.parapsilosis  isolates were 100% sensitive to all azoles tested  
and Nystatin B. C.glabrata was only 33% sensitive to fluconazole ,itraconazole 
and C. krusei was 100%  sensitive only  to nystatin B as it is inherently resistant to 
azoles.These findings were in accordance with the study conducted by MondolS 
et al128 which showed 82% of total Candida isolates were sensitive to fluconazole 
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by disc diffusion with highest rate of resistance among C.krusei (60%) followed 
by C.glabrata(30%) . 
 
 The resistance to fluconazole is of great concern because it is the azole 
which is most commonly used for superficial candidal infections as well as deep 
candidiasis . Since majority of the isolates from HVS and urine were C.albicans 
which were almost 100% susceptible  to fluconazole its use may be continued for 
empirical therapy of uncomplicated candidal vulvo-vaginitis and UTI. However 
timely monitoring of drug susceptibility must be done to detect the emerging 
resistance. 
 
  
Summary 
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SUMMARY 
 
 Around 200 antenatal patients both OPD and IPD attendees of Institute of 
obstetrics and gynaecology who fulfilled the inclusion criteria were included 
in the study. 
 The prevalence of infectious vaginitis among antenatal patients according to 
present study was 32.5% and it was most common in the age group 26-
30years. 
 Amsel’s criteria and Nugent’s score identified 17.5% and 21% of patients with 
BV respectively. 
 BV  was the most prevalent type of vaginitis (21%) followed by VVC(11.5%) 
and mixed infection was seen only in 3.5% of the patients. 
 UTI was found to be 16% with higher rate of infection  found in 3rd trimester 
(50%) predominantly seen in age group 26-30 years  and the difference was 
found to be statistically significant(p<0.05). 
  BV associated with UTI was seen in 35.7% of the patients. The association 
between BV and UTI was found to be statistically significant(p<0.05). 
  VVC associated with UTI was seen in 17.4% of the patients. However the 
association between VVC and UTI was  not statistically significant (p>0.05). 
   About 17.5% of vaginal isolates were found to be MDR with 28.5% of  
S.aureus  and 23% of  E.coli being MDR organisms. 
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 About 33% of the urinary isolates  were found as MDR which includes 50% 
E.coli and K.pneumoniae . An isolate of A.baumannii from urine was also 
MDR . 
 Candida albicans was the commonest species among Candida isolated from 
HVS(60.9%) and Urine (80%) . 
 C.tropicalis was the only Candida non albicans species isolated from(20%)  
urine specimen  and it was also found in (13%) HVS. C.tropicalis both from 
HVS and urine was 100%  sensitive to all azoles tested and Nystatin B.  
  An isolate of Candida krusei  inherently resistant to azoles  but sensitive to 
Nystatin was isolated from HVS culture. 
  
Conclusion 
  
 
92 
 
 
 
CONCLUSION 
 
 The conclusion from our study is that there is high prevalence of vaginitis 
among antenatal patients .  Bacterial vaginosis  was the most prevalent type of 
vaginitis in pregnant women which can contribute to adverse outcomes in 
pregnancy such as abortion ,premature rupture of membrane and preterm labor. 
Screening for BV among pregnant women at regular intervals or when 
symptomatic and an early treatment can not only reduce the  adverse outcomes 
but also decrease perinatal and maternal morbidity and mortality. Therefore it is 
recommended that antenatal health care facilities should incorporate screening of 
vaginitis among pregnant women and those with BV should be screened for UTI. 
Since douching ,smoking and multiple sexual partners are risk factors of BV , 
preventive measures against these factors should also be undertaken.  
 
 Increasing prevalence of MDR pathogens among urinary isolates  (33%) 
makes the empirical treatment of UTIs more difficult and choice of antibiotics 
should be based on urine culture and antimicrobial susceptibility testing . Thus 
proper and judicious use of antibiotics must alsobe encouraged.   
 
 Further large scale  studies are required to establish the association of UTI 
with infectious vaginitis in both pregnant and non pregnant women in order to 
identify the agents causing them so that prompt treatment can be initiated to 
prevent pregnancy associated complications in women of reproductive age group.                         
Colour Plates 
  
COLOUR PLATE 1 
Direct Gram stain of HVS showing normal vaginal epithelial cell. 
 
 
COLOUR PLATE 2 
Direct Gram stain from HVS showing clue cells in a patient with Bacterial 
vaginosis 
 
  
COLOUR PLATE 3 
Culture smear showing GPC in clusters from a patient with Bacterial vaginosis 
 
 
COLOUR PLATE 4 
Direct Gram stain picture of a patient with vulvovaginal candidiasis 
 
  
COLOUR PLATE 5 
Vaginal pH measurement for Amsel’s criteria : colour change corresponds to a  
pH between 8-9. 
 
 
COLOUR PLATE 6 
BAP showing βhemolytic  colonies of  S.agalactiae isolated from  HVS sample. 
 
 
COLOUR PLATE 7 
S.agalactiae showing positive CAMP test 
 
 
COLOUR PLATE 8 
S.agalactiae showing resistance to bacitracin and cotrimoxazole disc 
 
  
COLOUR PLATE 9 
CONS speciation by using novobiocin and polymyxin B disc 
 
 
COLOUR PLATE 10 
Biochemical reactions for  E.coli 
 
Tubes from left to right shows Indole - positive, TSI –Acid slant/acid butt, 
Citrate-negative,Urease- negative and Sugars: Glucose,lactose,sucrose,maltose 
and mannitol- fermented with acid and gas. 
  
Lactose fermenting flat colonies of E.coli on CLED 
 
 
COLOUR PLATE 11 
ESBL production in E.coli 
 
 
COLOUR PLATE 12 
Biochemical reactions for K.pneumoniae 
 
Tubes from left to right shows Indole - negative, TSI –Acid slant/acid butt with 
gas, Citrate-positive,Urease- positive and Sugars: Glucose,lactose,sucrose,maltose 
and mannitol- fermented with acid and gas. 
 
 
Lactose fermenting mucoid colonies of K.pneumoniae on MAC 
 
  
COLOUR PLATE 13 
Vancomycin MIC by E test for MRSA strain 
 
 
COLOUR PATE 14 
SDA culture of Candida albicans showing cream coloured,smooth  
and pasty colonies 
 
COLOUR PLATE 15 
Candida albicans showing positive Germ tube test 
 
 
COLOUR PLATE 16 
Sugar fermentation test showing reactions for C.albicans 
 
 
COLOUR PLATE 17 
Antifungal susceptibility by disc diffusion for Candida albicans 
\ 
 
COLOUR PLATE 18 
CHROM agar showing colonies of C.tropicalis 
 
COLOUR PLATE 19 
Sugar assimilation test showing reactions for C.tropicalis 
 
 
COLOUR PLATE 20: 
Modified Diamonds medium for culture of  T.vaginalis 
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APPENDIX-1 
ABBREVIATIONS 
ATCC  - American Type Culture Collection 
BAP  -  Blood Agar Plate 
BHI - Brain Heart Infusion 
BV  -  Bacterial vaginosis 
CA -  Clavulanic acid 
CAMP - Christie Atkins Munch Petersen 
CDC  -  Center for Disease Control and Prevention 
CFU -  Colony forming unit 
CLSI  -  Clinical laboratory standard Institute. 
CLED - Cystine lactose electrolyte deficient agar 
CONS - Coagulase Negative Staphylococcus aureus 
DNA - Deoxyribonucleic acid 
E test  -  Epsilon test (Epsilometer) 
ELISA - Enzyme Linked Immuno Sorbant Assay 
ESBL - Extended Spectrum Beta Lactamase 
GNB  -  Gram Negative Bacilli 
GPC -  Gram Positive Bacilli 
GMB - Glucose Methylene Blue medium 
GWC - Greyish White Colonies 
HVS  -  High vaginal swab 
H2S -  Hydrogen sulphide 
IUDs - Intra Uterine Devices 
KOH - Potassium Hydroxide 
MAC  -  Mac Conkey agar 
MDR  -  Multi Drug Resistant 
MHA  -  Mueller Hinton Agar 
MIC  -  Minimum inhibitory concentration 
MRSA  -  Methicillin resistant Staphylococcus aureus 
MSSA -   Methicillin sensitive Staphylococcus aureus 
TSI - Triple Sugar Iron Agar 
QC - Quality control 
SDA -   Sabourauds Dextrose Agar 
STI - Sexually Transmitted Infections 
TV - Trichomonas vaginalis 
VVC - Vulvovaginal candidiasis 
UTI - Urinary tract infection 
UPEC - UroPathogenic Escherichia coli 
 
ANTIBIOTICS 
CTX  - Cefotaxime 
CEC  -  Cefotaxime+clavulanic acid 
CX  - Cefoxitin 
IMP  - Imipenem 
AK  -  Amikacin 
GM  -  Gentamicin 
COT  - Trimethoprim – Sulfamethaxozole 
TET  - Tetracycline 
NIT - Nitrofurantoin 
NOR - Norfloxacin 
CAZ - Ceftazidime 
PT - Piperacillin tazobactum 
CIP - Ciprofloxacin 
ERY - Erythromycin 
HLG - High Level Gentamicin 
PEN - Penicillin 
VAN - Vancomycin 
CK - Chloramphenicol 
LZ - Linezolid 
CD - Clindamycin 
 
APPENDIX-II 
 
STAINS, REAGENTS AND MEDIA 
 
Gram staining: 
 Methyl violet(2%)-10g of Methyl violet in 100 ml Absolute alcohol in 1 litre of 
Distilled      water.(primary stain) 
 Grams Iodine-10g Iodine in 20 g KI (fixative) 
 Acetone-Decolourizing agent. 
 Carbolfuchsin(1%)-Secondary stain. 
 
MEDIA USED 
 
1.MacConkey agar medium 
Ingredients gram/liter 
 Peptone 20g 
 Lactose 10g 
 NaCl 5.g 
 Na- Deoxycholate 1.0 
 Neutral Red 0.03 
 Agar 15.0 
Fifty-two grams of dehydrated MacConkey agar medium was suspended in 1000 ml cold 
distilled water and boiled to dissolve the medium completely. The solution was then 
sterilized by autoclaving at 121°C and 15 lbs pressure for 15 minutes. 
 
2.Blood agar medium(5% sheep blood agar) 
Ingredients gram/liter 
 Peptone 10.00 
 Distilled water 1 ltr. 
 Sodium chloride 5.00 
 Agar 15.00 
Fourty grams of the dehydrated blood agar medium was suspended in 1000 mlcold 
distilled water in a flask and boiled to dissolve the medium completely. It was then 
sterilized by autoclaving at 121ºC and 15 lbs pressure for 15 minutes. The autoclaved 
materials were allowed to cool to a temperature of 45ºC in a water bath. Defibrinated5-
10% sheep blood was then added to the medium aseptically and distributed to sterile 
petridishes. Sterile media was stored in refrigerator at 4ºC for future use. 
 
3.Cystine lactose electrolyte deficient (CLED medium) 
Ingredients gram/liter 
 Peptone 4g 
 Tryptone 4g 
 Lab-Lemco powder 3g 
 Lactose 10g  
 L-cystine 0.128g 
 bromothymol blue 0.02g  
 agar 15g 
 water 1L 
 
Suspend the ingredients in the water, bring to the boil to dissolve. Sterilize by 
autoclaving at 121 ºC for 15minutes and mix well before pouring.. 
 Store the plates at 2–8 ºC, preferably sealed in plastic bags to prevent loss of moisture. 
Shelf-life: Up to 4 weeks or longer provided there is no change in the appearance of the 
medium to suggest contamination or a change in pH. 
 
4.Muller Hinton agar medium 
Ingredients gram/liter 
 Beef dehytrated infusion 300 
 Casein hydrolysate 17.50 
 Starch agar 1.50 
 Agar 10.00 
 
Thirty-eight grams of dehydrated Mueller Hinton agar medium was suspended in1000 ml 
cold distilled water and boiled to dissolve the medium completely. The solution was then 
sterilized by autoclaving at 121°C and 15 lbs pressure for 15 minutes. The autoclaved 
media was stored at 4°C.pH=7.4. 
 
5.Sabouraud dextrose  agar  with  antibiotics: 
 
INGREDIENT          Gm/ltr 
Peptone            10 gms 
Dextrose           40 gms 
Agar                 20 gms 
Distilled water   1000 gms 
Gentamicin          20 mg 
Final pH was  adjusted to  5.6 
 
 The  above ingredients  were  reconstituted in  one  litre  of   distilled  water. 
Dissolve  the powder  water  by  boiling. Gentamicin  is added  to  the  boiling  medium. 
The  medium  was then  removed  from  heating ,mixed  well and then  dispersed  in  
tubes  and  autoclaved  at  121deg celcius for  15  minutes   and the  final  pH was   
adjusted  to  5.6.The  tubes  were  cooled  in  slanted   position  and  later   the  slants  
were  stored in  refrigerator.   
 
6.Yeast  nitrogen base  medium (dehyrated  media): 
 
INGREDIENTS GMS/L INGREDIENTS GMS/L 
Ammonium 
sulphate 5.000 Niacin 0.0004 
L-Histidine 
hydrochloride 0.010 
p-Amino benzoic 
acid (PABA) 0.0002 
DL-Methionine 0.020 Pyridoxine hydrochloride 0.0004 
DL-Tryptophan 0.020 Riboflavin (Vitamin B2) 0.0002 
Biotin 0.000002 Thiamine hydrochloride 0.0004 
Calcium 
pantothenate 0.0004 Boric acid 0.0005 
Folic acid 0.00002 Copper  sulphate  0.00004 
Inositol 0.002 Potassium iodide 0.0001 
Ferric chloride 0.0002 Manganese sulphate 0.0004 
Sodium molybdate 0.0002 Zinc sulphate 0.0004 
Monopotassium 
phosphate 1.000 
Magnesium 
sulphate 0.500 
Sodium chloride 0.10 Calcium chloride 0.100 
 
Dissolve  6.7 gms  of  media  in  100 ml   0f  distilled  water. Serilise  by  filteration  and  
store  at  4 deg celcius. 
 
7.CHROM   agar candida  medium: 
 
INGREDIENTS                                               GMS/L 
 
Peptone,                                                     15 gms 
Yeast extract                                               4 gms 
Dipotassium hydrogen phosphate               1. gms 
Chromogenic mixture                                  7.22 gms 
Chloramphenicol                                        0.5 gms 
Agar                                                           15 gms 
pH  6.3±0.2  at  25°C) 
 
Suspend 42.72 grams in 1000 ml distilled water. Heat to boiling to dissolve the medium 
completely. Do not autoclave. Cool to 45-50°C. Mix well and pour into sterile Petri 
plates. 
MEDIA REQUIRED FOR BIOCHEMICAL IDENTIFICATION: 
 
1.Catalase test:3% hydrogen peroxide 
 
2.Oxidase reagent 
Composition 
Distilled water 10ml 
Tetramethyl-P- phenylenedimine 0.1 g 
 
3.Indole test 
Composition 
Ingredients amount 
 Peptone 20g 
 Sodium chloride 5g 
 Distilled water 1 L 
 After adjustment of the pH to 7.4 , sterilize by autoclaving at 1210C for 15 min. 
 Kovac.s reagent 
 Amyl or isoamyle alcohol 150ml 
 p . Dimethyl-aminobenzaldehyde 10g 
 Hydrochloric acid 50ml 
Dissolve the aldehyde in the alcohol and slowly add the acid and store in the refrigerator. 
 
4.Simmon’s Citrate Medium: 
 Koser’s medium 1 ltr 
 Agar 20g 
 Bromothymol blue 0.2% 40ml 
 Dispense, Autoclave at 121°for 15 min and allow to set as slopes. 
 
5.Triple Sugar Iron medium: 
 Beef extract 3g 
 Yeast extract 3g 
 eptone 20g 
 Glucose 1g 
 Lactose 10g 
 Sucrose 10g 
 Ferric citrate 0.3g 
 Sodium chloride 5g 
 Sodium thiosulphate 0.3g 
 Agar 12g 
 Phenol red 0.2% solution 12 ml 
 Distilled water 1 ltr 
Heat to dissolve the solids,add the indicator solution,mix and tube .Sterilize at 121° for15 
min and cool to form slopes with deep butts. 
 
6.Methyl Red test/Voges –Proskauer test: 
A.MR/VP broth(Glucose broth/phosphate buffer broth) 
 Polypeptone 7g 
 Glucose 5g 
 Dipotassium phosphate 5g 
 Distilled water 1Ltr 
 Final pH 6.9 
B.Reagents 
 
1. ∝-Napthol,5%(5gm in 100ml of absolute ethyl alcohol) 
2. Potassium hydroxide 40%(Potassium hydroxide in 100ml of Distilled water). 
 
7.Decarboxylase media: 
Moller decarboxylase broth base: 
 Ingredients gms/ml 
 Peptone 5 
 Beef extract 5 
 Bromocresol purple 0.01 
 Cresol red 0.005 
 Glucose 0.5 
 Pyridoxal 0.005 
 Aminoacid 
Add 10g of the levo form of the aminoacid for 1000 ml.mix and dispense in sterile tubes. 
 
8.Hugh-Leifson’s Oxidation-Fermentation test: 
 Peptone 2g 
 Sodium chloride 5g 
 D-glucose 10g 
 Bromothymol blue 0.03g 
 Agar 3g 
 Dipotassium phosphate 0.3g 
 Distilled water 1ltr 
 pH=7.1 
Basal medium is autoclaved.1%of sterile sugar solutions is added to the 
basalmedium.Dispense into the sterile test tubes without slant. 
ANNEXURE-I 
 
 
ANNEXURE-II 
 
PROFORMA 
 
 
 Name :                                                         IP  No: 
 Age:                                           Ward: 
 Occupation:                                        Contact No: 
 Address: 
 
 
 
 Presenting complaints 
 
 
 Obstetric history: G      P     L      A 
 
 Personal history 
 
 Past history 
 
 Treatment history 
 
 Any H/o symptoms in partner 
 
 H/o multiple partners 
 
 Clinical Diagnosis: 
 
 
 Microbiological investigation: 
 Direct Gram staining : 
 
 Amsel criteria scoring : 
 
 
 Nugent s criteria scoring: 
 
 Wet mount examination: 
 
 
 KOH examination: 
 
 
 HVS culture:      Mac conkeyagar: 
 
 
                           Blood agar: 
 
 
Sabouraud’s dextrose agar: 
 
 
                           Diamond’s media : 
 
 
 Urine Culture :   CLED Agar– 
 
 
Colony count – 
 
 
 
 Organisms identified from HVS culture: 
 
 
 Antibiotic sensitivity pattern – 
 
 Organisms identified from urine culture: 
 
 Antibiotic sensitivity pattern – 
 
 
 ANNEXURE-III 
 
CONSENT FORM 
STUDY TITLE :  
A STUDY ON MICROBIOLOGICAL PROFILE OF VAGINITIS & ITS 
ASSOCIATION WITH URINARY TRACT INFECTION  DURING 
PREGNANCY   
IN A TERTIARY CARE HOSPITAL 
  
I…………………………………………, hereby give consent to participate in the study 
conducted  by Dr.G.JabeenFathima, Post graduate at Institute of Microbiology, Madras 
Medical College, Chennai and to use my personal clinical data and the result of 
investigations for the purpose of analysis and to study the nature of the disease, I also 
give consent to give my clinical Specimen (high vaginal swabs and urine sample) for 
further investigations.I also learn that there is no additional risk in this study. I also give 
my consent for my investigator to publish the data in any forum or journal. 
 
   
Signature/ Thumb impression                                   Place                             Date 
Of the patient/ relative 
 
 
Patient Name & Address: 
 
 
Signature of the investigator: 
 
 
  Signature of guide: 
 
INFORMATION SHEET 
STUDY TITLE :  
A STUDY ON MICROBIOLOGICAL PROFILE OF VAGINITIS & ITS 
ASSOCIATION WITH URINARY TRACT INFECTION  DURING 
PREGNANCY  IN A TERTIARY CARE HOSPITAL 
 
INVESTIGATOR  : Dr.G.JabeenFathima, 
    Post Graduate, 
   Institute of Microbiology, 
 Madras Medical College, 
 Chennai - 600003 
 
GUIDE   : Dr.Thasneem Banu S M.D., 
    Professor of Microbiology, 
    Institute  of  Microbiology, 
    Madras  Medical  College, 
    Chennai - 600003 
  
• In pregnancy, normal vaginal microbiota, of lactobacilli is substituted by bacteria 
such as Gardnerellavaginalis, Mycoplasmahominis resulting in a signiﬁcant reduction 
in lactobacilli & increased pH  > 4 .5 which predispose to infection. 
•  Bacterial vaginosis (BV), vulvovaginal candidiasis (VC), and Trichomoniasis are 
responsible for 90% of cases of infectious vaginitis & it leads to obstetrical 
complications such as post abortion endometritis, chorioamnionitis, and premature 
labor . 
• The most common infection in preterm delivery is BV. 
• VC is an infection of the vagina caused by various species of Candida, a commensal 
fungus of the digestive and vaginal mucosae that become pathogenic under 
conditions such as  pregnancy . 
• Trichomoniasis is associated with PROM, premature delivery,  LBW,  postpartum 
endometritis, stillbirth, and neonatal death. 
• UTI in women develop when uropathogens almost always from the fecal flora 
colonize the vagina, ascend into the bladder and in some cases the kidney 
 
I am going tostudy on microbiological  profile of vaginitis & its association with 
urinary tract infection  during pregnancy in a tertiary care hospital .I am going to collect 
high vaginal swab and urine samples for this study and process them 
accordingly.200patients are included in this study after getting informed consent only. 
This study is entirely voluntary and patient can withdraw any time from this study. Extra 
cost will not be incurred to the patients in this study. Any doubt regarding this study will 
be willingly clarified. Results of the study will be published. In case of any doubt please 
contact Dr. G.JabeenFathima, Cell: 9894604826 
 
 
 
Amsel's 
criteria
Nugent's 
criteria
1 IP 35 3 + + - - - -  NO BV NO BV -
candida  
albicans
NG NG
2 IP 20 1 + - + - - - NO BV NO BV - - K.pneumoniae S S S S S S NG
3 OP 26 2 + - + - + - NO BV NO BV - - K.oxytoca (ESBL) S S S R R S NG
4 IP 23 3 - - + + - - NO BV NO BV - - NG
E.coli 10⁵ 
(ESBL)
S S S R S S
5 IP 23 1 + - - - - - NO BV BV - - NG NG
6 IP 26 3 + + + + - Clue cells BV BV - - P.mirabIlis S S R S S S
P.mirablis1
0⁵
S S S S S S
7 IP 28 3 - - + - + - NO BV NO BV - - NG NG
8 OP 25 2 + - - - - - NO BV NO BV - - NG NG
9 OP 29 3 + - - + - - BV BV - - NG E.coli 10⁵ S S S S S S
10 IP 22 2 + - - + + - NO BV NO BV -
candida 
albicans
NG
Candida 
albicans10⁵
11 IP 25 1 - - + - - - NO BV NO BV - - NG NG
12 IP 20 3 - - + - + - NO BV NO BV - - NG NG
13 IP 30 3 + + + + - Clue cells BV BV - -
K.pneumoniae 
(ESBL)
S S S R S S
P.mirablis1
0⁵
S S R S S S
14 IP 28 3 + - - + - Clue cells BV BV -
candida non 
albicans
NG
K.oxytoca1
0⁵(ESBL)
S S S R S S
15 IP 19 2 + - + - + - NO BV NO BV - - S.aureus (MSSA) S S S S S S NG
16 OP 21 2 + + - - - Clue cells BV BV - - NG NG
17 OP 25 2 + - + - - - NO BV NO BV - - NG NG
18 IP 26 3 - - + - - - NO BV NO BV - - NG NG
19 IP 33 3 - - + - - - NO BV NO BV - - NG NG
20 IP 40 3 + + - - - Clue cells BV BV -
candida non 
albicans
NG NG
21 IP 22 1 + - - - - - NO BV NO BV - - NG NG
22 IP 30 2 - - - + - - NO BV BV - - NG
Acinetobac
ter spp10⁵
R R R S R R
23 IP 29 2 + - + - + Clue cells BV BV - - E.coli(ESBL) S S S R R S NG
24 IP 20 3 + - + - - - BV BV - - E.coli S S S S S S NG
25 IP 29 2 + + - - - Clue cells BV BV -
candida 
albicans
NG NG
26 IP 20 3 + - - - - - NO BV NO BV - - NG NG
27 IP 20 2 + - - - - - NO BV NO BV - - NG NG
28 IP 24 2 + + + - - Clue cells BV BV - - S.aureus (MSSA) S R S S S S NG
29 OP 25 3 - - + - - - NO BV NO BV - - NG NG
30 OP 21 3 + - - + - - NO BV BV - - NG
S.aureus10⁵
(MSSA)
S S S S S S
31 IP 31 2 + + - - - Clue cells BV NO BV - - NG NG
32 IP 29 1 + - - - - - NO BV NO BV - - NG NG
Sample 
no.
IP/OP Age
BACTERIAL Vulvo - 
Vaginal 
Candidiasis
vaginal 
discomfort
wet 
mount
Trimester Discharge
Foul 
smell
Lower 
Abdominal 
pain
  Burning 
micturation
TETLZ CK
URINARY 
ISOLATE
CTX IMPCECHLGCOTCXPENPTCIPAKCAZ ERYGMTET PT CD IMP VAN
MASTER CHART
Bacterial Isolate
INFECTIOUS VAGINITIS
AK GM CIP
Trichomo
nas 
vaginalis
CXCECCTX CAZ COT PEN ERY NORNIT
Amsel's 
criteria
Nugent's 
criteria
Sample 
no.
IP/OP Age
BACTERIAL Vulvo - 
Vaginal 
Candidiasis
vaginal 
discomfort
wet 
mount
Trimester Discharge
Foul 
smell
Lower 
Abdominal 
pain
  Burning 
micturation
TETLZ CK
URINARY 
ISOLATE
CTX IMPCECHLGCOTCXPENPTCIPAKCAZ ERYGMTET PT CD IMP VAN
Bacterial Isolate
INFECTIOUS VAGINITIS
AK GM CIP
Trichomo
nas 
vaginalis
CXCECCTX CAZ COT PEN ERY NORNIT
33 OP 36 1 + - - - - - NO BV NO BV - - NG NG
34 IP 28 2 - - - + - - NO BV NO BV - - NG NG
35 IP 27 2 + + - - - Clue cells BV NO BV - - NG NG
36 IP 26 3 + - - - - - NO BV NO BV - - NG NG
37 IP 24 3 - - + - - - NO BV NO BV - - NG NG
38 IP 25 2 - - + - + - NO BV NO BV - - S.aureus (MSSA) S S R S S S NG
39 IP 30 3 + - - + - - NO BV NO BV - - NG
S.aureus10⁵
(MSSA)
S S R S S R
40 IP 21 3 + - - - - - NO BV NO BV - - NG NG
41 IP 23 2 + - - - + - NO BV NO BV - - NG NG
42 OP 24 3 + - - - - - NO BV NO BV - - NG NG
43 OP 26 2 + - + + - - BV NO BV - - K.pneumoniae S S S S S S
K.pneumon
iae10⁵
S S S S S S
44 IP 27 2 + - - - - - NO BV NO BV - - NG NG
45 IP 32 2 + - - - - - NO BV NO BV - - NG NG
46 IP 28 2 + - + - + - NO BV BV - - P.mirablis S S S S R S E.coli 10⁴ S S R S S S
47 OP 25 3 + + - - - Clue cells BV BV -
candida 
albicans
NG NG
48 OP 25 1 + - - + - - NO BV NO BV - - NG NG
49 IP 28 1 - - + - - - NO BV NO BV - - NG NG
50 IP 20 2 - - + - - - NO BV NO BV - - NG NG
51 OP 29 2 + - - - - - NO BV NO BV - - NG NG
52 IP 21 1 - - + - - - NO BV NO BV - - NG NG
53 IP 25 2 + - - - - - NO BV NO BV - - NG NG
54 IP 26 2 + - - - - - NO BV BV - - NG NG
55 IP 25 2 + - + - - - NO BV NO BV - - Strep.agalactiae S R S S S S NG
56 IP 22 3 + - - + + - BV BV - - E.coli S S S S S S E.coli10⁵ S S S S S S
57 IP 30 3 + - - - - - NO BV NO BV - - NG NG
58 IP 20 2 + + - - - - NO BV NO BV -
candida 
albicans
NG NG
59 OP 25 2 + - - - - - NO BV NO BV -
candida 
albicans
NG NG
60 IP 30 2 + - + + - Clue cells BV BV - - S.aureus (MRSA) R R R R R R R S S
Candida 
non 
albicans10⁵
61 IP 30 3 + - - - - - NO BV NO BV - - K.oxytoca S S R S R S E.coli10⁵ R S S S S S
62 OP 21 1 + - + - - - NO BV NO BV - - S.aureus (MSSA) R S R S S S NG
63 OP 25 3 - - + - - - NO BV NO BV - - NG NG
64 OP 31 2 + - - + - - NO BV NO BV - - K.oxytoca S S S S S S
K.pneumon
iae10³
R S S S S S
65 IP 20 3 - - - - - - NO BV NO BV - - NG NG
66 IP 27 2 + - - - - - NO BV BV - - E.coli(ESBL) S S S R S S NG
67 IP 22 3 - - + - + - NO BV NO BV - - E.coli(ESBL) R S R R R R S S NG
68 IP 23 2 + - - - - - NO BV NO BV - - NG NG
Amsel's 
criteria
Nugent's 
criteria
Sample 
no.
IP/OP Age
BACTERIAL Vulvo - 
Vaginal 
Candidiasis
vaginal 
discomfort
wet 
mount
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Foul 
smell
Lower 
Abdominal 
pain
  Burning 
micturation
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URINARY 
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Bacterial Isolate
INFECTIOUS VAGINITIS
AK GM CIP
Trichomo
nas 
vaginalis
CXCECCTX CAZ COT PEN ERY NORNIT
69 IP 24 1 + + - + - - NO BV NO BV - - NG NG
70 IP 25 2 + + - - - Clue cells BV NO BV -
candida non 
albicans
NG NG
71 IP 24 3 - - - + - - NO BV BV - - NG E.coli10³ R S R S S S
72 IP 20 2 + - - - - - NO BV NO BV - - NG NG
73 IP 25 2 - - + - - - NO BV NO BV - - NG NG
74 IP 25 3 + - - - - - BV BV - - NG NG
75 IP 24 3 + - - - - - NO BV NO BV - - NG NG
76 IP 29 2 + - + - - - NO BV NO BV - - K.pneumoniae S S R S S S NG
77 IP 21 3 - - + - - - NO BV NO BV - - NG NG
78 IP 23 1 + - - - + - NO BV BV - - NG NG
79 IP 22 2 + - - + - - NO BV NO BV - - NG
P.mirablis1
0⁵
S S S S R S
80 IP 27 1 + - - - - Clue cells BV BV - - NG NG
81 IP 22 2 + - - - - - NO BV NO BV - - NG NG
82 IP 21 2 - - + - - - NO BV NO BV - - NG NG
83 IP 34 2 + + - - - - BV BV -
candida 
albicans
NG NG
84 OP 24 3 + - - - - - NO BV NO BV - - NG NG
85 IP 26 2 + + - - - Clue cells BV BV - - NG NG
86 OP 34 3 + - - - - - NO BV NO BV - - NG NG
87 IP 25 3 + - + - - - BV BV - - NG NG
88 IP 24 1 + + - - - - NO BV NO BV - - NG NG
89 IP 34 2 + - - + - - NO BV NO BV - - NG NG
90 IP 22 1 + - - - - - BV BV -
candida non 
albicans
NG NG
91 IP 23 2 + - - - - - NO BV NO BV - - NG NG
92 IP 29 3 + - - - - - NO BV NO BV -
candida 
albicans
NG NG
93 IP 23 1 + + - - - Clue cells BV BV - - NG
P.aeruginos
a10⁵
S S S S S S
94 IP 23 3 + - - - - - NO BV NO BV - - NG NG
95 IP 29 3 - - + + - - NO BV NO BV - - E.coli (ESBL) S S R R R S NG
96 IP 28 3 + - - + - - NO BV NO BV - - NG
E.coli10⁵(ES
BL)
S S S R S S
97 IP 26 2 - - + - - Clue cells NO BV NO BV - - K.oxytoca (ESBL) S S R R R S NG
98 IP 32 3 + - - - + - NO BV BV - - S.aureus (MSSA) S S S S S S NG
99 IP 25 2 + - - - - - NO BV BV - - NG
K.oxytoca1
0⁵(ESBL)
S S S R S S
100 IP 31 2 + - - - - - NO BV NO BV - - CONS(MS) R S S S S S NG
101 IP 28 3 + - + - - - NO BV NO BV - - NG NG
102 IP 23 2 - - + - - - NO BV NO BV - - NG NG
103 IP 25 3 + - - - - - NO BV NO BV - - NG NG
Amsel's 
criteria
Nugent's 
criteria
Sample 
no.
IP/OP Age
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104 IP 42 2 + + - - - - NO BV NO BV - - NG
E.coli10⁵(ES
BL)
R S R R S S
105 IP 15 1 + - - - - - NO BV NO BV - - NG NG
106 IP 24 3 - - + - - - NO BV NO BV - - NG NG
107 IP 22 3 + - - - - - NO BV NO BV -
candida 
albicans
NG NG
108 IP 23 2 + - - - - - NO BV NO BV - - NG NG
109 IP 24 1 + - - - - - NO BV NO BV - - NG NG
110 IP 25 2 + + + - + - NO BV NO BV - - K.oxytoca R R S S S S NG
111 IP 24 2 - - + - - - NO BV NO BV - - E.coli S S S S S S NG
112 OP 23 3 - - + - - - NO BV NO BV - - NG NG
113 IP 26 2 + - - + - - NO BV BV - - NG
K.pneumon
iae10⁵
R R R R R R S S
114 IP 30 3 + - - - - - NO BV NO BV - - NG NG
115 IP 20 2 + - - - - - NO BV NO BV - - NG NG
116 IP 32 2 + - - - - - NO BV NO BV - - NG NG
117 IP 22 3 - _ - + - - NO BV NO BV - - NG NG
118 IP 25 2 + - - - - - NO BV NO BV - - NG NG
119 IP 23 2 + + - + - Clue cells BV BV - - NG
K.oxytoca1
0³
R S S S R S
120 OP 24 2 + - - - - - NO BV NO BV - - NG NG
121 IP 25 2 - - + - - - NO BV NO BV - - NG NG
122 IP 26 1 - - + - - - NO BV NO BV - - NG NG
123 IP 24 3 + - + - - Clue cells BV BV - - K.pneumoniae S S R S R S NG
124 IP 26 2 + + - - - - NO BV NO BV -
candida non 
albicans
NG NG
125 IP 33 1 + - - - - - BV NO BV - - NG NG
126 IP 34 1 - - + - - - NO BV NO BV - - NG NG
127 IP 27 2 + - - - - - NO BV NO BV - - NG
P.aeruginos
a10⁵
S R S S R S
128 IP 26 3 + - - + - - NO BV NO BV - - NG NG
129 IP 23 3 + - - - - - NO BV NO BV - - NG NG
130 IP 27 2 + + + - - Clue cells BV BV - - E.coli S S S S R S
Candida 
albicans10⁵
131 IP 33 1 + - - - + - NO BV NO BV - - NG NG
132 IP 25 2 + - - - - - NO BV NO BV - - NG NG
133 OP 23 1 + - - - - - NO BV NO BV -
candida non 
albicans
NG NG
134 IP 28 2 + - - - + - NO BV NO BV -
candida non 
albicans
NG NG
135 IP 21 3 + - - - - Clue cells NO BV NO BV - - NG NG
136 IP 24 3 + + - - - - NO BV NO BV - - NG NG
Amsel's 
criteria
Nugent's 
criteria
Sample 
no.
IP/OP Age
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137 IP 28 2 + - - - - - NO BV NO BV - - NG NG
138 IP 19 2 - - + + - - NO BV NO BV - - NG NG
139 IP 24 2 - - + + - - NO BV NO BV - - NG NG
140 IP 28 3 + - - - - - NO BV NO BV -
candida 
albicans
NG NG
141 IP 23 3 + + - - - - NO BV NO BV - - NG NG
142 IP 24 2 + - - - - - NO BV NO BV - - NG NG
143 OP 28 2 + - - - - - NO BV NO BV - - NG NG
144 IP 29 3 + - - - - Clue cells BV BV - - NG NG
145 OP 36 2 + - - - - - NO BV NO BV - - NG NG
146 OP 22 3 + - - - - - BV BV - - NG
Candida 
albicans10⁵
147 OP 33 2 + - - - - - NO BV NO BV - - NG NG
148 IP 18 1 + - - - + Clue cells BV BV -
candida 
albicans
NG
Enterococc
us spp10⁴
S S R S S S
149 OP 20 3 + + - - - - NO BV NO BV - - NG NG
150 OP 29 2 - - + + - - NO BV NO BV - - NG NG
151 IP 36 2 - - + + - - NO BV NO BV - - NG NG
152 IP 25 2 + - + - - - NO BV NO BV - - NG NG
153 IP 21 1 - - + + - - NO BV NO BV - - NG NG
154 IP 27 3 + + - - + - NO BV NO BV -
candida non 
albicans
NG
K.pneumon
iae10⁵
S R S R R S
155 IP 23 3 - - + - + - NO BV NO BV - - NG NG
156 IP 24 2 + - - - - - NO BV BV - - K.pneumoniae S S S R R S S NG
157 IP 20 3 + - - - - - NO BV NO BV - - NG E.coli10⁵ R R R R S R S S
158 OP 26 1 + - - - - - NO BV NO BV - - NG NG
159 OP 30 2 + - - + - - NO BV NO BV - - NG NG
160 IP 30 2 + + - - + - BV BV - - E.coli (ESBL) S S R R S S E.coli10⁵ R S R R S S
161 IP 31 2 + - - - - - NO BV NO BV - - NG
p.mirablis1
0³
S S R S S S
162 IP 31 2 + - - - - - NO BV NO BV - - K.oxytoca S S R S S S NG
163 IP 22 3 + - - - - - NO BV NO BV - - E.coli (ESBL) S S S R R S E.coli10⁵ S S R R S R
164 IP 28 1 + - - - - - NO BV NO BV - - NG NG
165 IP 25 2 - - + + - - NO BV NO BV - - NG NG
166 IP 18 3 + - - - - - NO BV NO BV - - NG NG
167 IP 27 3 + - - - - Clue cells BV BV - - NG
K.pneumon
iae10⁵
S S R S S S
168 OP 30 2 + - - + + - NO BV NO BV -
candida 
albicans
NG
Candida 
albicans10⁵
169 OP 15 2 + - - - - - NO BV NO BV - - NG NG
170 OP 24 2 + - - + - - NO BV BV - - E.coli (ESBL) S S S R S S E.coli10³ S S R S S S
171 IP 22 2 - - + - + - NO BV NO BV -
candida non 
albicans
NG NG
Amsel's 
criteria
Nugent's 
criteria
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no.
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172 IP 25 1 + - - - - - NO BV NO BV - - NG NG
173 IP 26 3 + - + - - - NO BV NO BV - - NG NG
174 IP 26 2 + - - - - - NO BV NO BV - - P.mirablis S S S S S S NG
175 IP 27 2 + - - - - - NO BV NO BV -
candida 
albicans
NG NG
176 IP 30 2 + - - - - - NO BV NO BV -
candida  
albicans
NG NG
177 IP 36 1 - - + + + - NO BV NO BV - - NG NG
178 IP 37 3 + - + - - - NO BV NO BV - - NG E.coli10⁵ S R S R S R
179 IP 33 3 + - + - - - NO BV NO BV - - NG NG
180 IP 27 3 + - - - - - BV NO BV - - NG NG
181 IP 31 2 + - - - - - NO BV NO BV - - NG NG
182 IP 23 2 + - - - - - NO BV NO BV - -
K.pneumoniae 
(ESBL)
S S S R S S
K.oxytoca1
0²
S R S S S S
183 IP 21 1 + - - - - - NO BV NO BV - - NG NG
184 IP 23 1 - - + + - - NO BV NO BV - - NG NG
185 IP 24 3 + + - - - Clue cells BV NO BV - - NG NG
186 IP 20 2 - - + - + - NO BV NO BV - - E.coli (ESBL) S S R R R S NG
187 IP 23 2 + - + - - NO BV NO BV - - K.oxytoca (ESBL) S S S R S S
K.oxytoca1
0⁵
S S S R S S
188 IP 25 2 + - - + - - NO BV NO BV - - CONS(MS) S R R R S S
s.aureus10³
(MSSA)
S S S S S S
189 IP 19 2 + - - - - - NO BV BV - - NG NG
190 IP 20 2 - - + + - - NO BV NO BV - - NG NG
191 IP 31 3 + - - - - - NO BV NO BV - - NG NG
192 IP 27 2 + + - - - - NO BV NO BV - - NG NG
193 IP 20 3 + + - - - - NO BV NO BV - - NG NG
194 IP 18 1 + - + - + - NO BV NO BV - - NG NG
195 IP 25 2 + - - - - - NO BV NO BV - - NG NG
196 IP 24 2 + - + + - - NO BV NO BV - - S.aureus(MRSA) S R R R R R R S S
P.aeruginos
a10³
S S R S S
197 IP 20 2 + - - - - - NO BV NO BV - - NG
S.aureus10⁵
(MSSA)
S R R R S R
198 IP 21 2 - - - + - - NO BV NO BV - - NG
Enterococc
us spp10⁵
S R S R S S
199 IP 35 2 + - - - - - NO BV NO BV - - NG NG
200 IP 21 2 - - + + - - NO BV NO BV - - E.coli(ESBL) S S S R S S E.coli10³ S S S S S S
